LanzaTech Global (LNZA) 10-Q9 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover	9 Months Ended
Cover	Sep. 30, 2023 shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-40282
Entity Registrant Name	LanzaTech Global, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	92-2018969
Entity Address, Address Line One	8045 Lamon Avenue
Entity Address, Address Line Two	Suite 400
Entity Address, City or Town	Skokie
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60077
City Area Code	847
Local Phone Number	324-2400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	196,055,228
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001843724
Amendment Flag	false
Document Fiscal Year Focus	2023
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock
Trading Symbol	LNZA
Security Exchange Name	NASDAQ
Warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	LNZAW
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 91,397	$ 83,045
Held-to-maturity investment securities	35,011	0
Trade and other receivables, net of allowance	10,085	11,695
Contract assets	24,313	18,000
Other current assets	16,677	11,157
Total current assets	177,483	123,897
Property, plant and equipment, net	22,818	19,689
Non-current held-to-maturity investment securities	9,780	0
Right-of-use assets	6,023	6,969
Equity method investment	9,594	10,561
Equity security investment	14,990	14,990
Other non-current assets	5,659	750
Total assets	246,347	176,856
Current liabilities:
Accounts payable	5,779	7,455
Other accrued liabilities	6,049	4,502
AM SAFE liability	0	28,986
Warrants	9,636	4,108
Contract liabilities	3,132	3,101
Accrued salaries and wages	7,196	7,031
Current lease liabilities	1,951	798
Total current liabilities	33,743	55,981
Non-current lease liabilities	5,250	6,615
Non-current contract liabilities	8,671	10,760
Fixed Maturity Consideration	7,020	0
FPA Put Option liability	38,092	0
Brookfield SAFE liability	23,350	50,000
Other long-term liabilities	1,746	1,591
Total liabilities	117,872	124,947
Redeemable convertible preferred stock, $0.0001 par value; 20,000,000 and 130,133,670 shares authorized, — and 129,148,393 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	0	480,631
Shareholders’ Deficit
Common stock, $0.0001 par value; 400,000,000 and 158,918,093 shares authorized, 196,055,228 and 10,422,051 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	19	1
Additional paid-in capital	939,868	24,782
Accumulated other comprehensive income	1,786	2,740
Accumulated deficit	(813,198)	(456,245)
Total shareholders’ equity (deficit)	128,475	(428,722)
Total liabilities, contingently redeemable preferred stock, and shareholders' equity	$ 246,347	$ 176,856

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Temporary equity par value (usd per share)	$ 0.0001	$ 0.0001
Temporary equity, shares authorized (in shares)	20,000,000	130,133,670
Temporary equity, shares issued (in shares)	0	129,148,393
Temporary equity, shares outstanding (in shares)	0	129,148,393
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized (in shares)	400,000,000	158,918,093
Common shares, shares issued (in shares)	196,055,228	10,422,051
Common shares, shares outstanding (in shares)	196,055,228	10,422,051

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues [Abstract]
Revenue from collaborative arrangements	$ 1,566,000	$ 760,000	$ 3,116,000	$ 1,733,000
Total revenue	19,605,000	8,072,000	42,168,000	25,781,000
Cost and operating expenses:
Cost of revenue from collaborative arrangements (exclusive of depreciation shown below)	(678,000)	(256,000)	(1,504,000)	(727,000)
Cost of revenue from related party transactions (exclusive of depreciation shown below)	(59,000)	(46,000)	(150,000)	(342,000)
Research and development expense	(16,645,000)	(14,260,000)	(51,839,000)	(39,858,000)
Depreciation expense	(1,376,000)	(1,211,000)	(3,981,000)	(3,433,000)
Selling, general and administrative expense	(11,808,000)	(7,258,000)	(41,095,000)	(19,482,000)
Total cost and operating expenses	(44,200,000)	(28,704,000)	(129,903,000)	(82,004,000)
Loss from operations	(24,595,000)	(20,632,000)	(87,735,000)	(56,223,000)
Other income (expense):
Interest income, net	1,249,000	8,000	3,164,000	3,000
Other expense, net	(1,517,000)	(1,176,000)	(29,912,000)	(1,100,000)
Total other income (expense), net	(268,000)	(1,168,000)	(26,748,000)	(1,097,000)
Loss before income taxes	(24,863,000)	(21,800,000)	(114,483,000)	(57,320,000)
Income tax expense	0	0	0	0
(Loss) gain from equity method investees, net	(463,000)	(467,000)	(941,000)	2,346,000
Net loss	(25,326,000)	(22,267,000)	(115,424,000)	(54,974,000)
Other comprehensive loss:
Foreign currency translation adjustments	(1,001,000)	(384,000)	(954,000)	(767,000)
Comprehensive loss	(26,327,000)	(22,651,000)	(116,378,000)	(55,741,000)
Unpaid cumulative dividends on preferred stock	0	(9,748,000)	(4,117,000)	(28,925,000)
Net loss allocated to common shareholders	$ (25,326,000)	$ (32,015,000)	$ (119,541,000)	$ (83,899,000)
Net loss per common share, basic (in dollars per share)	$ (0.13)	$ (3.47)	$ (0.70)	$ (9.10)
Net loss per common share, diluted (in dollars per share)	$ (0.13)	$ (3.47)	$ (0.70)	$ (9.10)
Weighted average shares outstanding of common stock - basic (in shares)	195,869,537	9,229,781	169,797,443	9,223,884
Weighted-average number of common shares outstanding - diluted (in shares)	195,869,537	9,229,781	169,797,443	9,223,884
Service
Cost and operating expenses:
Cost of revenue from contracts with customers (exclusive of depreciation shown below)	$ (11,862,000)	$ (3,694,000)	$ (28,835,000)	$ (15,307,000)
Service \| Nonrelated Party
Revenues [Abstract]
Revenue	14,162,000	4,917,000	32,119,000	18,519,000
Service \| Related Party
Revenues [Abstract]
Revenue	1,619,000	704,000	3,668,000	2,116,000
Tangible Products
Cost and operating expenses:
Cost of revenue from contracts with customers (exclusive of depreciation shown below)	(1,772,000)	(1,979,000)	(2,499,000)	(2,855,000)
Tangible Products \| Nonrelated Party
Revenues [Abstract]
Revenue	$ 2,258,000	$ 1,691,000	$ 3,265,000	$ 3,413,000

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY /DEFICIT - USD ($) $ in Thousands	Total	Previously Reported	Revision of Prior Period, Adjustment	Common Stock Outstanding	Common Stock Outstanding Previously Reported	Common Stock Outstanding Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income Previously Reported
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2022	129,148,393
Ending balance, temporary equity at Mar. 31, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021				9,217,160	2,106,934	7,110,226
Balance at the beginning at Dec. 31, 2021	(354,917)	$ (354,917)	$ 0	$ 1	$ 0	$ 1	$ 21,710	$ 21,711	$ (1)	$ (379,889)	$ (379,889)	$ 3,261	$ 3,261
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	738						738
Net loss	(16,778)									(16,778)
Issuance of common stock upon exercise of options (in shares)				5,031
Issuance of common stock upon exercise of options	7						7
Foreign currency translation	(28)											(28)
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2022				9,222,191
Balance at the end at Mar. 31, 2022	$ (370,978)			$ 1			22,455			(396,667)		3,233
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2021	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2021	$ 480,631	$ 480,631
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2022	129,148,393
Ending balance, temporary equity at Sep. 30, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2021				9,217,160	2,106,934	7,110,226
Balance at the beginning at Dec. 31, 2021	(354,917)	$ (354,917)	$ 0	$ 1	$ 0	$ 1	21,710	21,711	(1)	(379,889)	(379,889)	3,261	3,261
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(54,974)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2022				9,232,086
Balance at the end at Sep. 30, 2022	$ (407,640)			$ 1			23,800			(434,863)		3,422
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2022	129,148,393
Beginning balance, temporary equity at Mar. 31, 2022	$ 480,631
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2022	129,148,393
Ending balance, temporary equity at Jun. 30, 2022	$ 480,631
Beginning balance, Common stock, shares outstanding (in shares) at Mar. 31, 2022				9,222,191
Balance at the beginning at Mar. 31, 2022	(370,978)			$ 1			22,455			(396,667)		3,233
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	676						676
Net loss	(15,929)									(15,929)
Issuance of common stock upon exercise of options (in shares)				271
Foreign currency translation	(355)											(355)
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2022				9,222,462
Balance at the end at Jun. 30, 2022	$ (386,586)			$ 1			23,131			(412,596)		2,878
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2022	129,148,393
Ending balance, temporary equity at Sep. 30, 2022	$ 480,631
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	653						653
Net loss	(22,267)									(22,267)
Issuance of common stock upon exercise of options (in shares)				9,624
Issuance of common stock upon exercise of options	16						16
Transfer from foreign currency translation to investment	928
Foreign currency translation	(384)											(384)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2022				9,232,086
Balance at the end at Sep. 30, 2022	$ (407,640)			$ 1			23,800			(434,863)		3,422
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631
Increase (Decrease) in Temporary Equity [Roll Forward]
Exercise of a warrant, Series C and D Preferred Stock (in shares)	594,309
Exercise of a warrant, Series C and D Preferred Stock	$ 5,890
In-kind payment of preferred dividend	$ 241,529
Conversion of preferred stock into common stock (in shares)	(129,742,702)
Conversion of preferred stock into common stock	$ (728,050)
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023	0
Ending balance, temporary equity at Mar. 31, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the beginning at Dec. 31, 2022	$ (428,722)	$ (428,722)	$ 0	$ 1	$ 0	$ 1	24,782	24,783	(1)	(456,245)	(456,245)	2,740	2,740
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,505						3,505
RSA vesting (in shares)				2,535,825
Repurchase of equity instruments (in shares)				(771,141)
Repurchase of equity instruments	(7,650)						(7,650)
Net loss	(63,312)									(63,312)
Issuance of common stock upon exercise of options (in shares)				470,843
Issuance of common stock upon exercise of options	746						746
In-kind payment of preferred dividend	(241,529)									(241,529)
Conversion of preferred stock into common stock (in shares)				153,895,644
Conversion of preferred stock into common stock	728,050			$ 15			728,035
Recapitalization, net of transaction expenses (Note 3) (in shares)				28,898,374
Recapitalization, net of transaction expenses (Note 3)	236,973			$ 3			236,970
Forward Purchase Agreement prepayment	(60,547)						(60,547)
Reclassification of warrants to equity	1,800						1,800
Foreign currency translation	(49)											(49)
Ending balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023				195,451,596
Balance at the end at Mar. 31, 2023	$ 169,265			$ 19			927,641			(761,086)		2,691
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Dec. 31, 2022	129,148,393	29,521,810	99,626,583
Beginning balance, temporary equity at Dec. 31, 2022	$ 480,631	$ 480,631
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2023	0
Ending balance, temporary equity at Sep. 30, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Dec. 31, 2022	10,422,051			10,422,051	2,382,358	8,039,693
Balance at the beginning at Dec. 31, 2022	$ (428,722)	$ (428,722)	$ 0	$ 1	$ 0	$ 1	24,782	$ 24,783	$ (1)	(456,245)	$ (456,245)	2,740	$ 2,740
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (115,424)
Issuance of common stock upon exercise of options (in shares)	1,075,000
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2023	196,055,228			196,055,228
Balance at the end at Sep. 30, 2023	$ 128,475			$ 19			939,868			(813,198)		1,786
Beginning balance, Redeemable Convertible Preferred Stock (in shares) at Mar. 31, 2023	0
Beginning balance, temporary equity at Mar. 31, 2023	$ 0
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Jun. 30, 2023	0
Ending balance, temporary equity at Jun. 30, 2023	$ 0
Beginning balance, Common stock, shares outstanding (in shares) at Mar. 31, 2023				195,451,596
Balance at the beginning at Mar. 31, 2023	169,265			$ 19			927,641			(761,086)		2,691
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	5,122						5,122
Net loss	(26,786)									(26,786)
Issuance of common stock upon exercise of options (in shares)				222,906
Issuance of common stock upon exercise of options	331						331
Reclassification of warrants to equity	3,063						3,063
Foreign currency translation	96											96
Ending balance, Common stock, shares outstanding (in shares) at Jun. 30, 2023				195,674,502
Balance at the end at Jun. 30, 2023	$ 151,091			$ 19			936,157			(787,872)		2,787
Ending balance, Redeemable Convertible Preferred Stock (in shares) at Sep. 30, 2023	0
Ending balance, temporary equity at Sep. 30, 2023	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	3,151						3,151
Net loss	(25,326)									(25,326)
Issuance of common stock upon exercise of options (in shares)				380,726
Issuance of common stock upon exercise of options	560						560
Foreign currency translation	$ (1,001)											(1,001)
Ending balance, Common stock, shares outstanding (in shares) at Sep. 30, 2023	196,055,228			196,055,228
Balance at the end at Sep. 30, 2023	$ 128,475			$ 19			$ 939,868			$ (813,198)		$ 1,786

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net loss	$ (115,424)	$ (54,974)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	11,933	2,067
Gain on change in fair value of SAFE and warrant liabilities	(14,249)	(330)
Loss on change in fair value of the FPA Put Option and the Fixed Maturity Consideration liabilities	44,661	0
Provision for losses on trade and other receivables	700	0
Depreciation of property, plant and equipment	3,981	3,433
Amortization of discount on debt security investment	(933)	0
Non-cash lease expense	946	1,343
Non-cash recognition of licensing revenue	(1,700)	(1,620)
Loss (gain) from equity method investees, net	941	(2,346)
Net foreign exchange loss (gain)	423	1,311
Changes in operating assets and liabilities:
Accounts receivable, net	1,088	(8,710)
Contract assets	(6,488)	(3,270)
Accrued interest on debt investment	(178)	0
Other assets	(6,723)	(5,981)
Accounts payable and accrued salaries and wages	(1,484)	463
Contract liabilities	29	(471)
Operating lease liabilities	(212)	(1,518)
Other liabilities	1,124	(733)
Net cash used in operating activities	(81,565)	(71,336)
Cash Flows From Investing Activities:
Purchase of property, plant and equipment	(7,137)	(6,530)
Purchase of debt securities	(93,858)	0
Proceeds from maturity of debt securities	50,000	0
Forward Purchase Agreement prepayment	(60,096)	0
Purchase of additional interest in equity method investment	(288)	0
Origination of related party loan	(5,212)	0
Net cash used in investing activities	(116,591)	(6,530)
Cash Flows From Financing Activities:
Proceeds from issue of equity instruments of the Company	0	23
Proceeds from the Business Combination and PIPE, net of transaction expenses (Note 3)	213,381	0
Proceeds from exercise of options	1,637	0
Repurchase of equity instruments of the Company	(7,650)	0
Net cash provided by financing activities	207,368	23
Net increase (decrease) in cash, cash equivalents and restricted cash	9,212	(77,843)
Cash, cash equivalents and restricted cash at beginning of period	83,710	128,732
Effects of currency translation on cash, cash equivalents and restricted cash	(852)	145
Cash, cash equivalents and restricted cash at end of period	92,070	51,034
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of property, plant and equipment under accounts payable	219	107
Reclassification of capitalized costs related to the business combination to equity	1,514	0
Cashless conversion of warrants on preferred shares	5,890	0
Recognition of public and private warrant liabilities in the Business Combination	4,624	0
Reclassification of AM SAFE warrant to equity	1,800	0
Conversion of AM SAFE liability into common stock	29,730	0
Conversion of Legacy LanzaTech NZ, Inc. preferred stock and in-kind dividend into common stock	722,160	0
Reclassification of Shortfall warrant to equity	$ 3,063	$ 0

Description of the Business

Description of the Business	9 Months Ended
Description of the Business	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business LanzaTech Global, Inc., formerly known as AMCI Acquisition Corp. II (“AMCI”) prior to February 8, 2023 (the “Closing Date”) was incorporated as a Delaware corporation on January 28, 2021. On March 8, 2022, LanzaTech NZ, Inc. ("Legacy LanzaTech") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AMCI and AMCI Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of AMCI (“Merger Sub”). On February 8, 2023, Legacy LanzaTech completed its business combination with AMCI by which the Merger Sub merged with and into Legacy LanzaTech, with Legacy LanzaTech continuing as the surviving corporation and as a wholly owned subsidiary of AMCI (the “Business Combination”). The reporting entity is LanzaTech Global, Inc. and its subsidiaries (collectively referred to herein as “the Company” or "LanzaTech"). The Company is headquartered in Skokie, Illinois. The Company is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The Company’s customers leverage its proven proprietary gas fermentation technology platform to convert certain feedstock, including waste carbon gases, into sustainable fuels and chemicals such as ethanol. The Company performs related services such as feasibility studies, engineering services, and research and development ("R&D") in biotechnology for commercial and government customers. The Company also purchases low carbon chemicals produced at customer facilities employing the Company’s technology and sells it under the brand name CarbonSmart. We have also been developing the capabilities to produce single cell protein as a primary product from our gas fermentation platform. As of September 30, 2023, licensees of the Company’s technology operate four commercial-scale waste-to-gas ethanol plants in China and started operations of another one in India, with others currently in development in various countries, compared to three commercial scale waste-to-gas ethanol plants in China as of September 30, 2022. The Company has reclassified its warrants on preferred shares as of December 31, 2022 from other accrued liabilities to warrants on the condensed consolidated balance sheet to conform with current period presentation. This reclassification resulted in a decrease to other accrued liabilities and corresponding increase to warrants of $2,119 as of December 31, 2022. As a result of the Business Combination, the Company’s common stock trades under the ticker symbol “LNZA” and its Public Warrants trade under the ticker symbol “LNZAW” on the Nasdaq Stock Market. Prior to the consummation of the Business Combination, the Company’s common shares were listed on Nasdaq Stock Market under the symbol “AMCI” and the Public Warrants were listed on the Nasdaq Stock Market under the symbol “AMCI-W”. Unless otherwise indicated, amounts in these financial statements are presented in thousands, except for share and per share amounts.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in Legacy LanzaTech's Annual Report for the year ended December 31, 2022 included in the Company’s prospectus filed with the SEC on May 25, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of Legacy LanzaTech with the acquisition being treated as the equivalent of Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Legacy LanzaTech was deemed to be the predecessor, and the consolidated assets and liabilities and results of operations prior to February 8, 2023 are those of Legacy LanzaTech. Reported shares and earnings per share available to common stockholders, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Merger Agreement. The number of shares of preferred stock was also retroactively restated based on the exchange ratio. Variable Interest Entity (“VIE”) The Company makes judgments in determining whether an entity is a VIE and, if so, whether it is the primary beneficiary of the VIE and is thus required to consolidate the entity. A VIE is a legal entity that has a total equity investment that is insufficient to finance its activities without additional subordinated financial support or whose equity investors lack the characteristics of a controlling financial interest. The Company’s variable interest arises from contractual, ownership or other monetary interests in the entity, which changes with fluctuations in the fair value of the entity’s net assets. A VIE is consolidated by its primary beneficiary, the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company consolidates a VIE when the Company is deemed to be the primary beneficiary. The Company assesses whether or not the Company is the primary beneficiary of a VIE on an ongoing basis. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with applicable US GAAP. The Company holds interests in certain VIEs for which it has been determined the Company is not the primary beneficiary. The Company's variable interests primarily relate to entities in which the Company has a non-controlling equity interest. Although these financial arrangements resulted in holding variable interests in these entities, they do not empower the Company to direct the activities of the VIEs that most significantly impact the VIEs' economic performance. The Company's interests in the VIEs are, therefore, accounted for under the equity method of accounting or at fair value (including, when applicable, the practicability exception to fair value under ASC 321-10-35). Refer to Note 6 - Investments , for further information. The Company is exposed to the VIEs’ losses and other impairment indicators up to the carrying value of each investment and any amounts receivable from the VIE, less amounts payable. Refer to Note 12, Related Party Transactions , for further details on the transactions with VIEs. Going Concern The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. The Company had cash and cash equivalents of $91,397, short and long-term held-to-maturity debt investments of $44,791 and an accumulated deficit of $(813,198) as of September 30, 2023 and cash outflows from operations of $(81,565) and a net loss of $(115,424) for the nine months ended September 30, 2023. As a result of the Business Combination described in Note 1 closing on February 8, 2023, the Company received $153,285, which represents the proceeds from the Business Combination received net of (1) transaction expenses, (2) the PIPE investment and (3) the amount paid to ACM ARRT H LLC (“ACM”) and Vellar Opportunity Fund SPV LLC - Series 10 (“Vellar”) in relation to the Forward Purchase Agreement (see below). The Company has historically funded its operations through debt financing and issuances of equity securities. Based on the Company’s financial position as of the date the condensed consolidated financial statements were issued, the Company projects that it will be able to cover its liquidity needs for the next twelve months. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include fair value of equity awards granted to both employees and non-employees, revenue recognized over time, AM SAFE, Brookfield SAFE, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants. The Company uses the percentage of completion for both input and output methods to recognize revenue over time for certain contracts with customers. Under the output method, the Company exercises judgment and estimation when determining the percentage of completion against the total transaction price initially estimated. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance. Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 hereunder. Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates. Segment Information The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and assess performance. While the Company offers a variety of services and operates in multiple countries, the Company’s business operates in one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, most of the Company’s service offerings are deployed in a similar way, and the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. There are no segment managers who are held accountable by the CODM, or anyone else, for operations, operating results, and planning for components below the consolidated level. Accordingly, the Company has determined that it has a single reportable and operating segment. See Note 5 - Revenues , for disaggregation of the Company’s revenues by customer location and contract type. Foreign Currencies The Company’s reporting currency is the U.S. Dollar. The Company has certain foreign subsidiaries where the functional currency is the local currency. All of the assets and liabilities of these subsidiaries are translated to U.S. dollars at the exchange rate in effect at the balance sheet date, income and expense accounts are translated at average rates for the period, and shareholders’ equity accounts are translated at historical rates. The effects of translating financial statements of foreign operations into the Company’s reporting currency are recognized in accumulated other comprehensive income. The Company also has foreign subsidiaries that have a functional currency of the U.S. dollar. Purchases and sales of assets and income and expense items denominated in foreign currencies are remeasured into U.S. dollar amounts on the respective dates of such transactions. Net realized and unrealized foreign currency gains or losses relating to the differences between these recorded amounts and the U.S. dollar equivalent actually received or paid are included within other expense, net in the condensed consolidated statements of operations and comprehensive loss. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023 and December 31, 2022 , the Company had $91,397 and $83,045 of cash and cash equivalents, respectively. Restricted Cash The Company is required to maintain a cash deposit with a bank which consists of collateral on certain travel and expense programs maintained by the bank. The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of September 30, 2023 and December 31, 2022. As of September 30, 2023 December 31, 2022 Cash and cash equivalents $ 91,397 $ 83,045 Restricted cash (presented within Other current assets) 673 665 Cash, cash equivalents and restricted cash $ 92,070 $ 83,710 Trade and Other Receivables Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience. As of September 30, 2023 and December 31, 2022, the Company recognized an allowance for doubtful accounts of $1,751 and $1,051, respectively. Investment securities The Company classifies investment securities according to their purpose and holding period. All investment securities are debt securities that have been classified as held-to-maturity (“HTM”) because the Company has both the ability and intent to hold the securities to maturity. HTM debt securities are comprised of U.S. Treasury bills, U.S. Treasury notes, Yankee bonds, and corporate debt. HTM debt securities are carried at amortized cost, which is original cost net of periodic principal repayments and amortization of premiums and accretion of discounts. Accrued interest receivable is recorded within trade and other receivables, net of allowance on the condensed consolidated balance sheets. Amortization of premiums and accretion of discounts are computed using the contractual level-yield method (contractual interest method), adjusted for actual prepayments. The contractual interest method recognizes the income effects of premiums and discounts over the contractual life of the securities based on the actual behavior of the underlying assets, including adjustments for actual prepayment activities, and reflects the contractual terms of the securities without regard to changes in estimated prepayments based on assumptions about future borrower behavior. Held-to-maturity securities are evaluated individually on a quarterly basis for expected credit losses. If applicable, an allowance for credit losses is recorded with a corresponding credit loss expense (or reversal of credit loss expense). The allowance for credit losses excludes uncollectible accrued interest receivable, which is measured separately. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded at fair value as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and adjusted to the current fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss in other expense, net on the condensed consolidated statement of operations and comprehensive loss (see Note 7 - Warrants ). Forward Purchase Agreement On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM . On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”). At the Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Maturity Consideration, on the Maturity Date, the Company shall pay to the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5,079 (the “Share Consideration”). If the Purchasers were to utilize their Optional Early Termination to terminate the FPA early, neither the Maturity Consideration nor the Share Consideration would be due to the Purchasers. The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to an in-substance written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion. The FPA consists of three freestanding financial instruments compromising the in-substance written put option (“FPA Put Option”), the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), and the Share Consideration. The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The difference between the initial value of the derivative, including Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”), and the Prepayment Amount was recorded in the condensed consolidated statement of operations and comprehensive loss. Subsequent changes in fair value of the derivative liability are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss. The Prepayment Amount was accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares. The Minimum Maturity Consideration, representing 7,500,000 less 5,916,513 multiplied by $2.00 or $3,167, and the Share Consideration are considered to be free-standing debt instruments. The Company has elected to measure these using the Fair Value Option (“FVO”) under ASC 825, Financial Instruments (“ASC 825”). As both the Minimum Maturity Consideration and the Share Consideration will be paid on the same terms and at the same time, these are accounted for together and referred to as the “Fixed Maturity Consideration”. The Variable Maturity Consideration is captured as part of the in-substance written put derivative liability (the FPA Put Option), as noted above. The Fixed Maturity Consideration is recorded as long-term liability on the condensed consolidated balance sheets. The initial value of the Fixed Maturity Consideration is recorded through the condensed consolidated statement of operations and comprehensive loss. Subsequent changes in fair value of the Fixed Maturity Consideration are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss. Prior to filing these financial statements on Form 10-Q, we determined that our prior interpretation of the accounting guidance applicable to certain elements of the Forward Purchase Agreement (“FPA”) was incorrect. As a result, we have revised the accounting treatment of the FPA in our financial statements as of September 30, 2023 to reclassify the Prepayment Amount of $60.5 million, previously recorded as part of a net non-current derivative asset in the condensed consolidated balance sheet, to the equity section of the condensed consolidated balance sheet. The remaining liability balance of $38.1 million associated with the FPA, including the Minimum Maturity Consideration and the Share Consideration, are now reflected as non-current liabilities in our condensed consolidated balance sheet. The change in accounting for the FPA did not have any impact on our liquidity, cash flows or results of operations for the third quarter. We intend to restate our financial statements for the quarters ended March 31, 2023 and June 30, 2023 to be consistent with this accounting treatment. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop and optimize novel biocatalysts, related processes and technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart). Revenue is measured based on the consideration specified in a contract with a customer. The Company records taxes collected from customers and remitted to governmental authorities on a net basis. The Company’s payment terms are between 30-60 days and can vary by customer type and products offered. Management has evaluated the terms of the Company’s arrangements and determined that they do not contain significant financing components. Biorefining The Company provides feasibility studies and basic design and engineering services used for detailed design, procurement, and construction of commercial plants that utilize the Company’s technologies, along with the sale of microbes and media. The services provided are recognized as a performance obligation satisfied over time. Revenue is recognized using the output method based on milestone completion, the cost-to-cost input method for certain engineering services, or the percentage of completion method as performance obligations are satisfied. Revenue for the sale of microbes and media is at a point in time, depending on when control transfers to the customer. The Company licenses intellectual property to generate recurring revenue, in the case of running royalties, or one-time revenue, in the case of fixed consideration royalties, when its customers deploy the Company’s technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later. Joint Development and Contract Research The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and contract research, including projects with the U.S. Department of Energy and other US and foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606 , and estimates its variable consideration under the expected value method. Revenue is not recognized in advance of customer acceptance of a milestone when such acceptance is contractually required. Payments for R&D services with no contractual payments are not due from customers until a technical report is submitted; therefore, a contract asset is recognized at milestone completion but prior to the submission of a technical report. The contract asset represents the Company’s right to consideration for the services performed at milestone completion. Occasionally, customers provide payments in advance of the Company providing services which creates a contract liability for the Company. The contract liability represents the Company's obligation to provide services to a customer. CarbonSmart The Company purchases chemical building blocks from the customers who have deployed our proprietary technologies in their biorefining plants and sells them as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from contract with customers - tangible products in the condensed consolidated statements of operations and comprehensive loss. Collaboration Arrangements The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements , which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the condensed consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access; Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities; and Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement , approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability. Concentration of Credit Risk and Other Risks and Uncertainties Revenue generated from the Company’s customers outside of the United States for the three months ended September 30, 2023 and 2022 was approximately 75% and 54%, respectively. Revenue generated from the Company’s customers outside of the United States for the nine months ended September 30, 2023 and 2022 was approximately 75% and 61%, respectively. As of September 30, 2023 and December 31, 2022, approximately 49% and 35%, respectively, of trade accounts receivable and unbilled accounts receivable were due from customers located outside the United States. As of September 30, 2023 and December 31, 2022, the value of property, plant, and equipment outside the United States was immaterial. The Company’s revenue by geographic region based on the customer’s location is presented in Note 5, Revenues . Customers Customers representing 10% or greater of revenue were as follows for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer A 36 % — % 39 % 10 % Customer B 7 % 27 % 8 % 24 % Customer C — % 21 % — % 10 % Stock-Based Compensation In exchange for certain employee and director services, compensation is given in the form of equity-based awards. The Company accounts for equity-based compensation in accordance with ASC 718, Compensation – Stock Compensation. Accordingly, equity-classified awards are recorded based on the grant date fair value and expensed over the requisite service period for the respective award. Liability-classified awards are remeasured at the end of each reporting period and expensed based on the percentage of requisite service that has been rendered. The Company’s equity-based awards include stock option awards, restricted stock units, stock-appreciation rights (“SARs”) and restricted stock issued by the Company, which vest based on either time and/or the achievement of certain market or performance conditions. The Company records forfeitures as they occur. Compensation expense is recognized in the Company’s consolidated statements of operations and comprehensive loss, primarily within research and development expenses. For awards with only service conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. For awards with market or performance conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for each tranche of the award. Compensation expense resulting from performance awards is recognized over the requisite service period when it is probable that the performance condition will be met. The recognized compensation expense for performance awards is adjusted based on an estimate of awards ultimately expected to vest. The Company estimates the fair value of service and performance-based options and SARs using a Black-Scholes option pricing model that uses assumptions including expected volatility, expected term, and the expected risk-free rate of return. The Company estimates the fair value of market-based RSUs using the Monte Carlo simulation model that uses assumptions including expected volatility, and the derived service period. The Company uses peer data to determine expected volatility and expected term. The Company estimates the fair value of RSUs based on the closing market price of its common stock on the date of measurement. Recently Adopted and Issued Accounting Pronouncements There are no recently adopted or issued accounting pronouncements that are expected to have a material impact on the Company.

Reverse Recapitalization

Reverse Recapitalization	9 Months Ended
Reverse Recapitalization	Sep. 30, 2023
Reverse Recapitalization [Abstract]
Reverse Recapitalization	Reverse Recapitalization On February 8, 2023, Legacy LanzaTech and AMCI consummated the merger contemplated by the Merger Agreement (see Note 1 - Description of the Business ). Immediately following the Business Combination, there were 196,222,737 shares of common stock outstanding with a par value of $0.0001. Additionally, there were outstanding warrants to purchase 12,574,200 shares of common stock. The Business Combination was accounted for as a reverse recapitalization in accordance with US GAAP. Under this method, while AMCI was the legal acquirer, it has been treated as the “acquired” company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of pre-combination Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of pre-combination Legacy LanzaTech. Reported shares and earnings per share available to holders of the Company’s common stock and preferred shares, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Business Combination (approximately one pre-combination Legacy LanzaTech share to 4.3747 of the Company’s shares). Upon closing of the Business Combination, the shareholders of AMCI, including AMCI founders, were issued 10,398,374 shares of common stock of the Company. In connection with the closing, holders of 8,351,626 shares of common stock of AMCI were redeemed at a price per share of approximately $10.16. In connection with the Closing, 18,500,000 shares of common stock of the Company were issued to PIPE investors. 15,500,000 of those shares were issued at a price per share of $10.00. The remaining 3,000,000 shares were issued upon conversion of the AM SAFE liability. The Company incurred $7,223 in transaction costs relating to the Business Combination and recorded those costs against additional paid-in capital in the condensed consolidated balance sheet. The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were: Shares Percentage Legacy LanzaTech shares 167,324,363 85.3 % Public stockholders 10,398,374 5.3 % PIPE shares 18,500,000 9.4 % Total 196,222,737 100 % The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows: Recapitalization Cash - AMCI trust account 1 $ 64,090 Cash - PIPE financing 155,000 Less: Transaction costs allocated to equity (5,709) Effect of the Business Combination and PIPE financing $ 213,381 __________________ (1) The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses. The following table reconciles the elements of the Business Combination and PIPE financing to the change in additional paid-in capital on the condensed consolidated statement of changes in redeemable convertible preferred stock and shareholders’ equity / deficit: Recapitalization Cash - AMCI trust account $ 64,090 Public Warrants and Private Placement Warrants recorded on the Closing Date (4,624) Cash - PIPE financing 155,000 Conversion of the AM SAFE 29,730 Transaction costs allocated to equity (7,223) $ 236,973 Less: par value of shares held by PIPE investors and public stockholders (3) Total additional paid-in capital from recapitalization $ 236,970

Net Loss Per Share

Net Loss Per Share	9 Months Ended
Net Loss Per Share	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common stock equivalents of the Company, including equity-classified share-based compensation, the Brookfield SAFE, warrants, and contingently redeemable preferred stock, to the extent dilutive. Earnings per share calculation for all periods prior to the Business Combination have been retrospectively restated to the equivalent number of shares reflecting the exchange ratio established in the Merger Agreement of 4.3747. The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss for basic and diluted earnings per common share $ (25,326) $ (22,267) $ (115,424) $ (54,974) Unpaid cumulative dividends on preferred stock — (9,748) (4,117) (28,925) Net loss allocated to common shareholders $ (25,326) $ (32,015) $ (119,541) (83,899) Denominator: Weighted-average shares used in calculating net loss per share, basic and diluted 195,869,537 9,229,781 169,797,443 9,223,884 Net loss per common share, basic and diluted (1) $ (0.13) $ (3.47) $ (0.70) $ (9.10) __________________ (1) In periods in which the Company reports a net loss, all common stock equivalents are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share. As of September 30, 2023 and 2022, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following: September 30, 2023 2022 Redeemable convertible preferred stock (if converted) — 129,148,393 Options 17,021,827 16,584,305 RSUs 7,042,901 — RSAs — 2,535,825 Brookfield SAFE 5,000,000 — Warrants 16,657,686 985,278 Total 45,722,414 149,253,801 The preferred shares automatically converted into common shares upon the Business Combination at a 1:1 ratio. On February 8, 2023, upon conversion of the preferred shares, the cumulative accrued, declared and unpaid dividends on the preferred shares became payable. The total amount of cumulative accrued, undeclared and unpaid dividends was approximately $241,529 on the Closing Date. As stipulated by the Merger Agreement, this amount was divided by 10 and resulted in the issuance of an additional 24,152,942 common shares. Prior to the Business Combination, the additional 129,148,393 of common stock equivalents resulting from any such conversion are not included in the computation of diluted net loss per share because doing so would be anti-dilutive. In connection with the AM SAFE and Brookfield SAFE, see Note 9 - Fair Value , the Company could issue additional potential shares of common stock. Shares related to the AM SAFE were issued on the Closing Date. Shares related to the Brookfield SAFE and AM SAFE warrant have not been issued as of September 30, 2023. The terms of the AM SAFE warrant became exercisable for a fixed number of shares as of the Closing Date, see Note 7 – Warrants . As a result, these common stock equivalents are included in the warrants line item in the potential share table above as of September 30, 2023. The per share issuance price for the Brookfield SAFE upon closing of the Business Combination is the liquidity price as defined in the Brookfield SAFE agreement. As a result of the Business Combination, the Brookfield SAFE became convertible into a maximum number of shares, which is included in the table above as of September 30, 2023. None of these common stock equivalents are included in the computation of diluted net loss per share until actually issued because doing so would be anti-dilutive.

Revenues

Revenues	9 Months Ended
Revenues	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenues	Revenues Disaggregated Revenue The following table presents disaggregated revenue in the following categories (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Contract Types: Licensing $ 1,515 $ 540 $ 2,902 $ 1,620 Engineering and other services 10,912 2,955 25,572 12,630 Biorefining revenue $ 12,427 $ 3,495 $ 28,474 $ 14,250 Joint development agreements 1,933 1,571 5,049 4,018 Contract research 2,987 1,315 5,380 4,100 Joint development and contract research revenue $ 4,920 $ 2,886 $ 10,429 $ 8,118 CarbonSmart (tangible product) 2,258 1,691 3,265 3,413 Total Revenue $ 19,605 $ 8,072 $ 42,168 $ 25,781 The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements (in thousands). Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue from partners in collaborative agreements 1,566 $ 760 3,116 1,733 The following table presents disaggregation of the Company’s revenues by customer location for the three and nine months ended September 30, 2023 and 2022 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 North America $ 4,847 $ 4,412 $ 11,309 $ 12,361 Europe, Middle East, Africa (EMEA) 10,732 1,287 25,088 7,894 Asia 2,137 1,888 2,690 4,151 Australia 1,889 485 3,081 1,375 Total Revenue $ 19,605 $ 8,072 $ 42,168 $ 25,781 Contract balances The following table provides changes in contract assets and liabilities (in thousands): Current Contract Assets Current Contract Liabilities Non-current Contract Liabilities Balance as of January 1, 2023 $ 18,000 $ 3,101 $ 10,760 Additions to unbilled accounts receivable 43,901 — — Increases due to cash received — 4,486 — Unbilled accounts receivable recognized in trade receivables (37,413) — — Decrease on revaluation on currency (175) — (73) Reclassification from long-term to short-term — 2,016 (2,016) Reclassification to revenue as a result of performance obligations satisfied — (6,471) — Balance as of September 30, 2023 $ 24,313 $ 3,132 $ 8,671 The increase in contract assets was mostly due to unbilled accounts receivable resulting from revenue recorded under contracts with customers where the Company performed engineering and other services, while the decrease in contract liabilities was primarily due to the recognition of revenue during the period related to advance payments previously received by the Company for engineering and other services contracts with customers. As of September 30, 2023 and December 31, 2022 the Company had $10,085 and $11,695, respectively, of billed accounts receivable, net of allowance. The contract liability balance comprises unconditional payments received from the Company’s customers prior to the satisfaction of the related performance obligations. Such amounts are anticipated to be recorded as revenues when services are performed in subsequent periods. The Company expects to recognize the amounts classified as current contract liabilities in revenue within one year or less and those classified as non-current within two to three years. Remaining performance obligations Transaction price allocated to the remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue that will be recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including the length of the contract term compared to the research term and the existence of customer specific acceptance rights. Remaining performance obligations consisted of the following (in thousands): As of September 30, 2023 December 31, 2022 Current $ 3,132 $ 3,101 Non-current 8,671 10,760 Total $ 11,803 $ 13,861

Investments

Investments	9 Months Ended
Investments	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments	InvestmentsHTM Debt Securities HTM debt securities are comprised of U.S. Treasury bills and notes, Yankee debt securities, and corporate debt securities. HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment. September 30, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes $ 20,178 $ — $ (7) $ 20,171 $ 45 Corporate debt securities 14,833 3 (26) 14,810 109 Total debt securities due within a year $ 35,011 $ 3 $ (33) $ 34,981 $ 154 After 1 year through 5 years Corporate debt 6,780 3 (3) 6,780 24 Yankee debt securities 3,000 2 — 3,002 — Total debt securities due after 1 year through 5 years $ 9,780 $ 5 $ (3) $ 9,782 $ 24 Total HTM Debt Securities 44,791 8 (36) 44,763 178 The Company regularly reviews held-to-maturity securities for declines in fair values that are determined to be credit related. As of September 30, 2023, the Company did not have an allowance for credit losses related to held-to-maturity securities. Equity investments The Company’s equity investments consisted of the following (in thousands): As of September 30, 2023 December 31, 2022 Equity Method Investment in LanzaJet $ 9,594 $ 10,561 Equity Security Investment in SGLT 14,990 14,990 Total Investment $ 24,584 $ 25,551 LanzaJet On May 13, 2020, the Company contributed $15,000 in intellectual property in exchange for a 37.5% interest (“Original Interest”) of LanzaJet, Inc. (“LanzaJet”) in connection with an investment agreement (“Investment Agreement”). The Company accounts for the transaction as a revenue transaction with a customer under ASC 606. The licensing and technical support services provided are recognized as a single combined performance obligation satisfied over the expected period of those services, beginning May 2020 through December 2025. During the three months ended September 30, 2023 and 2022, the Company recognized revenue from this arrangement of $565 and $540 respectively, net of intra-entity profit elimination. During the nine months ended September 30, 2023 and September 30, 2022, the Company recognized revenue from this arrangement of $1,701 and $1,620 respectively, net of intra-entity profit elimination and has associated deferred revenue of $6,047 and $8,062, as of September 30, 2023 and December 31, 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $107 and $132 for the three months ended September 30, 2023, and 2022, respectively. Intra-entity profits related to revenue contracts with LanzaJet are $313 and $395 for the nine months ended September 30, 2023 and 2022, respectively. Intra-entity profits are amortized over a 15-year period through 2034. Between February 1, 2021 and April 4, 2021, LanzaJet closed two additional rounds of investment which reduced the Company's Original Interest to approximately 25%. In connection with the LanzaJet Note Purchase Agreement as described in Note 12 - Related Party Transactions , LanzaJet issued warrants that are exercisable for $0.01 by the holder when the related funds are drawn by LanzaJet. The warrants held by LanzaTech and other lenders meet the accounting criteria for in-substance common stock at the time the related note commitment is drawn by LanzaJet and the warrants become exercisable. As of September 30, 2023, LanzaTech’s ownership was diluted to approximately 23.15% because LanzaTech received proportionally fewer warrants than the other investors. The Company recorded a gain on dilution of $502. LanzaTech’s ownership is subject to further dilution to approximately 22.38% if LanzaJet draws additional funds committed in the LanzaJet Note Purchase Agreement and the remaining warrants are exercisable by the holders. The Company retained its contingent right to receive additional interest in LanzaJet of up to 45 million shares for no additional consideration. The carrying value of our equity method investment in LanzaJet as of September 30, 2023 and December 31, 2022 was approximately $2,200 and $3,700 less than our proportionate share of our equity method investees’ book values, respectively. The basis differences are largely the result of a difference in the timing of recognition of variable consideration to which we may become entitled in exchange for our contribution of intellectual property to LanzaJet. The variable consideration we may receive will be in the form of additional ownership interests and the majority of the basis difference will reverse in connection with recognition of that variable consideration. In connection with a sublicense agreement to LanzaJet under our license agreement with Battelle Memorial Institute (“Battelle”), LanzaTech remains responsible for any failure by LanzaJet to pay royalties due to Battelle. The fair value of LanzaTech’s obligation under this guarantee was immaterial as of September 30, 2023 and December 31, 2022. SGLT On September 28, 2011, the Company contributed RMB 25,800 (approx. $4,000) in intellectual property in exchange for 30% of the registered capital of Beijing Shougang LanzaTech Technology Co., LTD (“SGLT”). As of December 31, 2022, the Company’s interest in SGLT’s registered capital is approximately 9.31% as a result of the admittance of new investors during the year. As of September 30, 2022 , the Company no longer had significant influence over the operating and financial policies of SGLT due to the significant and sustained decrease in SGLT's technological dependence on LanzaTech. As such, the Company ceased applying the equity method and from October 1, 2022 and forward, the Company accounts for its investment in equity security of SGLT using the alternative measurement principals as permitted under ASC 321, Investments - Equity Securities, because SGLT's fair value is not readily determinable. For the three and nine months ended September 30, 2023 , there was no change in the value of the investment in SGLT. As of September 30, 2023 and December 31, 2022, there were no impairments of equity investments. During the three months and nine months ended September 30, 2023 and 2022, the Company received no dividends from equity investments. See Note 12 - Related Party Transactions

Warrants

Warrants	9 Months Ended
Warrants	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants	Warrants Warrants on preferred shares The Company had issued warrants to purchase its preferred shares representing 985,278 preferred shares. In connection with the closing of the Business Combination, all warrants were exercised on a cashless basis and are no longer outstanding. The warrants were exercised for 594,309 shares of preferred stock, which were converted at the closing of the Business Combination into shares of common stock. The exercise prices of the warrants ranged from $3.36 to $4.56 as of the closing of the Business Combination. The warrants were accounted for as liabilities in accordance with ASC 480, and were presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within other expense, net on the condensed consolidated statements of operations and comprehensive loss. Immediately before the exercise of these warrants, the associated warrant liability was marked-to-market a final time to $5,890, which is equal to the number of shares issued multiplied by the share price of $9.91 on the date of exercise, February 8, 2023. AM SAFE warrant The warrant related to the AM SAFE (“AM SAFE warrant”) was accounted for as a liability in accordance with ASC 480 prior to the consummation of the Business Combination and was presented within warrants on the condensed consolidated balance sheet as of December 31, 2022. As a result of the Business Combination and issuance of the PIPE shares, the number of common shares available under the AM SAFE warrant equals 300,000. The exercise price of the AM SAFE warrant is $10.00 per share as determined on the Closing Date. The AM SAFE warrant expires at the earliest of (a) the fifth anniversary of the Business Combination, (b) the consummation of a dissolution event and (c) a change of control. Due to the AM SAFE warrant becoming exercisable for a fixed number of shares at a fixed exercise price, it no longer meets the criteria for liability accounting under ASC 480 and meets the criteria for equity classification under ASC 815-40. As a result, on the Closing Date, the AM SAFE warrant was marked-to-market a final time to $1,800 through other expense, net on the condensed consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital on the condensed consolidated balance sheet. Shortfall Warrants On March 27, 2023, the Company issued an aggregate of 2,073,486 warrants to ACM and 2,010,000 warrants to Vellar pursuant to the Forward Purchase Agreement (collectively, the “Shortfall Warrants”), as further described in Note 2 - Summary of Significant Accounting Policies . Each Shortfall Warrant entitles the registered holder to purchase one share of common stock at a price of $10.00 per share, subject to adjustment in the event that the Company sells, grants or otherwise issues common stock or common stock equivalents at an effective price less than the then current exercise price of the Shortfall Warrants, at any time commencing on or after March 27, 2023. The Shortfall Warrants expire on the fifth anniversary of their issuance. On the issuance date, the Shortfall Warrants met the definition of a derivative but did not qualify for the exception from derivative accounting under the indexation guidance and therefore met the criteria for liability classification under ASC 815. On May 13, 2023, the Company amended the Shortfall Warrant agreement. Under the amended agreement, the Shortfall Warrants meet the requirements for equity classification under ASC 815-40. Consequently, the Company recorded a gain of $2,042 as of the date of the amendment to reflect the fair value of $3,063 at the date of the amendment through other expense, net on the condensed consolidated statements of operations and comprehensive loss and reclassified the Shortfall Warrants to additional paid-in capital on the condensed consolidated balance sheet. Public Warrants and Private Placement Warrants As part of AMCI’s initial public offering (“IPO”), AMCI issued warrants to third-party investors where each whole warrant entitles the holder to purchase one share of the Company’s common stock at an exercise price of $11.50 per share (the “Public Warrants”). Simultaneously with the closing of the IPO, AMCI completed the private sale of warrants where each warrant allows the holder to purchase one share of the Company’s common stock at $11.50 per share. Additionally, prior to the consummation of the Business Combination, AMCI issued warrants for the settlement of a working capital loan. The working capital warrants have the same terms as the private sale of warrants issued at the IPO. Warrants sold in the private sale at the IPO and the warrants issued to convert the working capital loan are collectively referred to as the “Private Placement Warrants”. On the Closing Date and as of September 30, 2023 , 7,499,924 Public Warrants and 4,774,276 Private Placement Warrants remained outstanding. These warrants expire on the fifth anniversary of the Business Combination or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Business Combination, provided that the Company has an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Once the warrants become exercisable, the Company may redeem the outstanding warrants: a. in whole and not in part; b. at a price of $0.01 per warrant; c. upon a minimum of 30 days’ prior written notice of redemption to each warrant holder; and d. if, and only if, the closing price of the common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three trading days before we send the notice of redemption to the warrant holders. The Public Warrants and Private Placement Warrants are recognized as derivative liabilities in accordance with ASC 815. Accordingly, the Company recognized the warrant instruments as liabilities at fair value as of the Closing Date, with an offsetting entry to additional paid-in capital and adjusts the carrying value of the instruments to fair value through other expense, net on the condensed consolidated statement of operations and comprehensive loss at each reporting period until they are exercised. As of September 30, 2023, the Public Warrants and Private Placement Warrants are presented within warrants on the condensed consolidated balance sheet.

Forward Purchase Agreement

Forward Purchase Agreement	9 Months Ended
Forward Purchase Agreement	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Forward Purchase Agreement	Forward Purchase Agreement As discussed in Note 2 - Summary of Significant Accounting Policies , the FPA consists of the prepaid forward contract and the Fixed Maturity Consideration. The prepaid forward contract is evaluated as an in-substance written put option that meets the definition of a derivative, referred to as the FPA Put Option in our condensed consolidated balance sheets. The value of the FPA Put Option represents the economics of the written put option, including the Variable Maturity Consideration and is valued at $38,092 as of September 30, 2023 . The Fixed Maturity Consideration is valued at $7,020 as of September 30, 2023. This represents the fair value of the Share Consideration and Fixed Maturity Consideration and is measured in accordance with the FVO. Expensed transaction costs, representing the stock acquisition fees, in the amount of $451 are recorded in other expense, net.

Fair Value

Fair Value	9 Months Ended
Fair Value	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value	Fair Value The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022 (in thousands): Fair Value Measurement as of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 37,370 $ — $ — $ 37,370 Total assets $ 37,370 $ — $ — $ 37,370 Liabilities: FPA Put Option liability $ — $ — $ 38,092 $ 38,092 Fixed Maturity Consideration — — 7,020 7,020 Brookfield SAFE liability — — 23,350 23,350 Private placement warrants — — 5,060 5,060 Public warrants 4,575 — — 4,575 Total liabilities $ 4,575 $ — $ 73,522 $ 78,097 Fair Value Measurement as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 523 $ — $ — $ 523 Liabilities: Warrants on preferred shares — — 2,119 2,119 Brookfield SAFE liability — — 50,000 50,000 AM SAFE warrant — — 1,989 1,989 AM SAFE liability — — 28,986 28,986 Total Liabilities $ — $ — $ 83,094 $ 83,094 Forward Purchase Agreement The fair value upon issuance of the FPA (both the FPA Put Option liability and Fixed Maturity Consideration) and the change in fair value from issuance to September 30, 2023 net of the Prepayment Amount, is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss. The fair value of the FPA was estimated using a Monte-Carlo Simulation in a risk-neutral framework. Specifically, the future stock price is simulated assuming a Geometric Brownian Motion (“GBM”). For each simulated path, the forward purchase value is calculated based on the contractual terms and then discounted back to present. Finally, the value of the forward is calculated as the average present value over all simulated paths. The Fixed Maturity Consideration was also valued as part of this model as the timing of the payment of the Fixed Maturity Consideration may be accelerated if the Maturity Date is accelerated. The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of September 30, 2023: September 30, 2023 Stock price $ 4.67 Term (in years) 2.36 Expected volatility 50.0 % Risk-free interest rate 4.89 % Expected dividend yield — % Warrants on preferred shares The fair value of the warrants on preferred shares was estimated using a Black-Scholes option pricing model. Since the warrants were exercised on February 8, 2023 (see Note 7 - Warrants, for a description of the valuation on that date), the following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding as of December 31, 2022: December 31, 2022 Stock price $ 5.21 Weighted average exercise price $ 3.96 Term (in years) 1.1 Expected volatility 73.4 % Risk-free interest rate 4.47 % Expected dividend yield — % Shortfall Warrants The fair value of the Shortfall Warrants was estimated using a Black-Scholes option pricing model. The following table represents the weighted average inputs used in calculating the fair value of the Shortfall Warrants as of May 13, 2023 when the Shortfall Warrant Agreement was amended and the Shortfall Warrants were marked-to-market and reclassified to additional paid-in capital on the condensed consolidated balance sheet: May 13, 2023 Stock price $ 3.42 Weighted average exercise price $ 10.00 Term (in years) 4.87 Expected volatility 54.0 % Risk-free interest rate 3.46 % Expected dividend yield — % SAFE Liabilities and AM SAFE Warrant The change in fair value between reporting periods for the Brookfield SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023. The change in fair value between December 31, 2022 and the Closing Date for the AM SAFE liability is included in other expense, net in the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2023. See below for further details on the AM SAFE liability and see Note 7 - Warrants for further details on the AM SAFE warrant. The Company’s AM SAFE liability (until conversion to shares on the Closing Date), AM SAFE warrant (until conversion to an equity classified warrant on the Closing Date) and Brookfield SAFE liability are mark-to-market liabilities and are classified within Level 3 of the fair value hierarchy as the Company is using a scenario-based approach which allowed the Company to estimate the implied value of the business based on the terms of the SAFE. Significant unobservable inputs included probability and expected term. Probability was based upon the likelihood of the Company closing a transaction with a special purpose acquisition company. The expected term was based on the anticipated time until the SAFE investments would have a conversion event. At conversion on the Closing Date, the AM SAFE liability converted into 3,000,000 shares of common stock. As of the Closing Date, the AM SAFE had a fair value of $29,730, which equals the closing price of approximately $9.91 on the Closing Date, multiplied by the number of shares issued. The AM SAFE was adjusted to its fair value on the Closing Date prior to settlement. As of December 31, 2022, the AM SAFE had a fair value of $28,986 and was recorded within current liabilities on the condensed consolidated balance sheet. Significant inputs for Level 3 AM SAFE liability fair value measurement at December 31, 2022 are as follows: Near Term Long-Term Key assumptions: Probability weighting 61 % 39 % Time to conversion (in years) 0.1 0.8 Liquidity price 100 % 90 % Discount rate 24.7 % 24.7 % At conversion to equity classification on February 8, 2023, the AM SAFE warrant was valued usin g a Black-Scholes option pricing model as the warrant became exercisable for a fixed number of shares at a fixed price as described in Note 7 - Warrants . The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023: February 8, 2023 Stock price $ 9.91 Term (in years) 5.00 Expected volatility 70.0 % Risk-free interest rate 3.82 % Expected dividend yield — % Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows (in thousands): Near Term Long-Term Key assumptions: Probability weighting 61 % 39 % Remaining life (in years) 5.0 5.0 Volatility 75 % 75 % Interest rate 3.99 % 3.99 % Time to conversion (in years) 0.1 0.8 Risk-free interest rate 4.12 % 4.75 % Dividend yield — % — % Significant inputs for Level 3 Brookfield SAFE liability fair value measurement at December 31, 2022 are the timing and likelihood of project financings under the Brookfield Framework Agreement. The Brookfield SAFE is legal form debt that the Company has elected to measure using the FVO under ASC 825. As of September 30, 2023, no part of the Brookfield SAFE has converted to Company common shares as a qualifying financing had not yet occurred and no project investments were presented. There were no cash flows associated with the Brookfield SAFE in the nine months ended September 30, 2023. As of its issuance date, the fair value of the Brookfield SAFE is equal to the investment amount of $50,000 based on the orderly nature of the transaction. The value as of December 31, 2022 remains the same due to the proximity of the valuation date to the issuance date (i.e., less than two months) and the absence of events which would indicate a change in expected payoffs to the investor. As of December 31, 2022 the same expectations about sufficient projects meeting the agreed-upon investment criteria pursuant to the Brookfield Framework Agreement are maintained. As such the Brookfield SAFE’s fair value is estimated to be $50,000, as of December 31, 2022. As of September 30, 2023, the Company expects to present sufficient projects to Brookfield to result in the Brookfield SAFE being automatically converted into shares. Since the liquidity price is not expected to change during the life of the Brookfield SAFE, the number of shares that Brookfield receives is fixed. Based on this expectation, the value of the Brookfield SAFE is equal to the Brookfield SAFE's as-converted value, which is the initial purchase amount, divided by the liquidity price, times the stock price, resulting in an estimated fair value of $23,350 recorded on the condensed consolidated balance sheet. Significant inputs for Level 3 Brookfield SAFE measurement at September 30, 2023 are as follows: September 30, 2023 Initial purchase amount $ 50,000 Liquidity price $ 10.00 Stock price $ 4.67 Public Warrants and Private Placement Warrants For the Public Warrants, the Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value and recognized an increase in the fair value of the liability of approximately $2,100 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to September 30, 2023. The fair value of the Private Placement Warrants was estimated using a Black-Scholes option pricing model. For the nine months ended September 30, 2023, the Company recognized an increase in the fair value of liabilities of approximately $2,912 on the condensed consolidated statements of operations and comprehensive loss within other expense, net representing the change in fair value from the Closing Date to September 30, 2023. The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of September 30, 2023 and at the time of the Business Combination: September 30, 2023 Stock price $ 4.67 Exercise price $ 11.50 Term (in years) 4.36 Expected volatility 52.5 % Risk-free interest rate 4.66 % Expected dividend yield — % The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands): Fixed Maturity Consideration Shortfall Warrants Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Brookfield SAFE Private placement warrants Balance as of January 1, 2023 $ — $ — $ (2,119) $ (28,986) $ (1,989) $ (50,000) $ — Recognized as a result of the Business Combination — — — — — — (2,148) (Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (7,020) (3,063) (3,770) (744) 189 26,650 (2,912) Conversion of warrants to preferred shares — — 5,889 — — — — Conversion of SAFE liability to equity classification — — — 29,730 — — — Conversion of warrant to equity classification — 3,063 — — 1,800 — — Balance as of September 30, 2023 $ (7,020) $ — $ — $ — $ — $ (23,350) $ (5,060) Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Balance as of January 1, 2022 $ (1,145) $ (28,271) $ (1,729) Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (427) 1,050 (293) Balance as of September 30, 2022 $ (1,572) $ (27,221) $ (2,022)

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to federal and state income taxes in the United States, as well as income taxes in foreign jurisdictions in which it conducts business. The Company does not provide for federal income taxes on the undistributed earnings of its foreign subsidiaries as such earnings are reinvested indefinitely. The Company and its foreign subsidiaries have historically been loss generating entities that have resulted in no excess earnings to consider for repatriation and accordingly there are no deferred income taxes recognized for the three and nine months ended September 30, 2023 and 2022. The Company recorded an income tax expense of $0 for the three and nine months ended September 30, 2023 and 2022, representing an effective tax rate of 0%. The difference between the U.S. federal statutory rate of 21% and the Company's effective tax rate in the three and nine months ended September 30, 2023 and 2022 is primarily due to a full valuation allowance related to the Company's U.S. and foreign deferred tax assets. The Company reassesses the need for a valuation allowance on a quarterly basis. If it is determined that a portion or all of the valuation allowance is not required, it will generally be a benefit to the income tax provision in the period such determination is made. The Company conducts business in multiple jurisdictions within and outside the United States. Consequently, the Company is subject to periodic income tax examinations by domestic and foreign income tax authorities. The Company is subject to audits for tax years 2017 and onward for federal purposes. There are tax years which remain subject to examination in various other state and foreign jurisdictions that are not material to the Company's financial statements.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
Share-Based Compensation	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation The Company adopted the LanzaTech 2023 Long-Term Incentive Plan (the “LTIP”) in conjunction with the closing of the Business Combination. The LTIP provides for grants of a variety of awards to employees, directors, and other service providers to the Company, including, but not limited to stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock-based awards or cash incentives. Prior to the effective date of the closing of the Business Combination, the Company granted awards under the LanzaTech NZ Inc. 2013 Stock Plan, the LanzaTech NZ Inc. 2015 Stock Plan, and the LanzaTech NZ, Inc. 2019 Stock Plan, (collectively, the “Prior Stock Plans”). Equity Classified Awards: RSUs Under the LTIP, the Company has granted two types of RSUs: time-based RSUs, and market-based RSUs. Time-based RSUs granted to employees and other service providers (other than directors) are generally subject to a three-year annual pro-rata vesting schedule whereby the awards generally vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to grantee’s continued service through each vesting date. However, vesting will accelerate in certain circumstances (e.g., retirement, death, disability, or a qualified termination in connection with a change in control). Time-based RSUs granted to directors are subject to a one-year vesting schedule and the full award vests on the first anniversary of the vesting commencement date, subject to the director’s continued service through the vesting date. However, vesting will accelerate in certain circumstances (e.g., removal in connection with a change in control). The market-based RSUs have both a time-based and a market-based vesting component. Both components must be met for the award to vest. The market-based RSUs are subject to the same three-year annual pro-rata vesting schedule as the employee time-based RSUs. The market-based vesting component is satisfied if on any date during the period beginning on the 151st date following the vesting commencement date and ending on the fifth anniversary of the vesting commencement date, the average closing price of a share of the Company’s common stock, equals or exceeds $11.50, determined using the closing share price from the 20 trading days preceding such determination date. A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table: Number of RSUs (thousands) Weighted Average Grant Date Fair Value Time-based Market-based January 1, 2023 — — $ — Granted 3,143 3,930 2.49 Vested (2) — 3.45 Cancelled/forfeited (28) — 3.43 September 30, 2023 3,113 3,930 $ 2.49 The Company recorded compensation expense related to the RSUs of $1,895 and $4,594 for the three and nine months ended September 30, 2023. Unrecognized compensation costs as of September 30, 2023 was $12,936 and will be recognized over a weighted average of 1.98 years. Stock Options In accordance with the LTIP and Prior Stock Plans, grantees have also been granted stock options to purchase common shares. The exercise prices of each stock option was no less than the fair market value price of the Company’s common shares determined as of the date of grant. The stock options generally vest over the course of two Stock option awards outstanding as of September 30, 2023 and changes during the period ended September 30, 2023 were as follows: Shares subject to option (thousands) Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (thousands) Outstanding at January 1, 2023 14,661 $ 1.48 5.80 Vested and expecting to vest at January 1, 2023 14,661 1.48 5.80 Exercisable at January 1, 2023 11,203 $ 1.44 5.15 Granted 3,556 3.77 — Exercised (1,075) 1.53 — Cancelled/forfeited (120) 1.76 — Outstanding at September 30, 2023 17,022 $ 1.95 6.21 $ 47,653 Vested and expecting to vest at September 30, 2023 17,022 1.95 6.21 47,653 Exercisable at September 30, 2023 11,208 $ 1.48 4.98 $ 36,026 The Company recorded compensation expense related to the options of $1,234 and $653 for the three months ended September 30, 2023 and 2022, respectively, and $4,443 and $2,067 for the nine months ended September 30, 2023 and 2022. Unrecognized compensation costs as of September 30, 2023 was $9,550 and will be recognized over a weighted average of 2.29 years. Restricted Stock Awards (“RSAs”) Under the Prior Stock Plans, the Company granted RSAs which become eligible to vest upon the satisfaction of a time-based service condition. However, in order to vest, a liquidity event, defined as acquisition, asset transfer, or initial listing, must occur within 10 years from the grant date. Upon a liquidity event, if the participant’s service has not terminated, the entire RSA award vests in full, whether or not previously eligible for vesting. If the participant’s service has terminated and they have satisfied the time-based service condition, the RSAs that are outstanding and eligible for vesting immediately vest in full upon liquidity event. The time-based service requirements of the RSAs have a maximum term of three years from the date of grant. As of December 31, 2022, there were 2,535,825 outstanding unvested RSAs with a weighted average grant date fair value of $1.08. The Business Combination constituted a “liquidity event” which caused the vesting of all such outstanding, unvested RSAs. The vesting of the RSAs resulted in compensation expense of $0 and $2,741 for the three and nine months ended September 30, 2023, respectively. There was no compensation expense recorded in the comparable periods in 2022, because the Company concluded that the liquidity event performance condition was not probable of being satisfied at the time. In connection with the vesting of these RSAs, certain holders of the RSAs surrendered 771,141 shares in a withhold to cover transaction to fund the payment of applicable tax withholding on their behalf by the Company. This resulted in a total cash payment of $7,650 by the Company to the Internal Revenue Service for the applicable tax withholding associated with this vesting event. Liability-Classified Awards Phantom RSUs Under a phantom equity sub-plan of the LTIP, certain non-US employees of the Company were provided with Phantom RSUs that can only be settled in cash and are therefore recorded as a liability. The Phantom RSUs have a graded vesting schedule and vest in 3 equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Grantees are entitled to receive a cash payment equal to the fair market value of a share multiplied by the number of vested RSUs as of the applicable vesting date. Phantom SARs Under a phantom equity sub-plan of the LTIP, certain non-US employees of the company were provided with Phantom SARs that can only be settled in cash and are therefore recorded as a liability. The Phantom SARs have a graded vesting schedule and vest in three equal tranches on the first, second, and third anniversaries of the vesting commencement date, subject to the employee meeting the requisite service requirements. Phantom SARs expire 10 years after the grant date and entitle the grantee to receive a cash payment upon exercise of the award equal to the excess of the fair market value of a share on the date of exercise over the exercise price multiplied by the number of SARs exercised.

Related Party Transactions

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions As of September 30, 2023 and December 31, 2022, the Company has an equity ownership in LanzaJet and SGLT (see Note 6 - Investments for further details). The table below summarizes amounts related to transactions with these related parties (in thousands) : As of September 30, 2023 December 31, 2022 Accounts receivable $ 763 $ 1,821 Notes receivable 5,351 — Accounts payable 635 3,195 The following table presents revenue from related parties per disaggregated revenue categories: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue from related parties, included within Licensing 1,515 540 2,902 1,620 Revenue from related parties, included within Engineering and other services 104 164 766 496 The main transactions with related parties are described below: LanzaJet The Company and LanzaJet have entered into a master service agreements defining the terms when LanzaJet is a subcontractor for some of the Company’s projects, and conversely, when the Company is a subcontractor for LanzaJet’s projects. The accounts payable balance is for work that LanzaJet performed as a subcontractor to the Company. In connection with the formation of LanzaJet, the Company entered into a transition services agreement with LanzaJet, refer to Note 6 - Investment s, for more information. The transition services agreement generally sets out the respective rights, responsibilities and obligations of the Company and LanzaJet with respect to R&D services, access to office and laboratory space, business development and other administrative support services. The transition services agreement may be terminated by mutual consent of the Company and LanzaJet, by LanzaJet at any time, and by the Company upon breach or non-payment by LanzaJet. There are no substantive termination penalties in the event the Company terminates. For the three months ended September 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $97 and $23, respectively, under the transition services agreement. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue from related parties of approximately $209 and $148, respectively, under the transition services agreement. The Company also provides certain engineering and other services related to a gas-to-jet demonstration plant currently in development by LanzaJet pursuant to the Investment Agreement described in Note 6 - Investments . In connection with this agreement, the Company recognized $6 and $39 in revenue, respectively, for the three months ended September 30, 2023 and 2022, and recognized revenue of $446 and $170, respectively, for the nine months ended September 30, 2023 and 2022. LanzaJet Note Purchase Agreement On November 9, 2022, the Company and the other LanzaJet shareholders entered into a Note Purchase Agreement (the “Note Purchase Agreement”), pursuant to which LanzaJet Freedom Pines Fuels LLC (“FPF”), a wholly owned subsidiary of LanzaJet, will issue, from time to time, notes in an aggregate principal amount of up to $147.0 million (the “Notes”), comprised of approximately $113.5 million aggregate principal amount of 6.00% Senior Secured Notes maturing December 31, 2043 and $33.5 million aggregate principal amount of 6.00% Subordinated Secured Notes maturing December 31, 2043. The Company committed to purchase $5.5 million of Subordinated Secured Notes, which was funded on May 1, 2023. The Senior Secured Notes are secured by a security interest over substantially all assets of FPF, and both the Senior Secured Notes and the Subordinated Secured Notes are secured by a security interest over the intellectual property owned or in-licensed by LanzaJet. Each purchaser of Notes under the Note Purchase Agreement also received a warrant for the right to purchase 575,000 shares of common stock of LanzaJet for each $10 million of Notes purchased by such purchaser for an exercise price of $0.01 per share. The warrants are exercisable when the related loan commitment is funded, and may be exercised until the earlier of the third anniversary following the date the holder’s loan commitment is fully funded, or the end of the availability period as defined in the Note Purchase Agreement if the commitment has not been fully funded. In the case of the Company, LanzaTech received warrants to purchase 316,250 shares of common stock of LanzaJet, which became exercisable by the Company when the note was funded on May 1, 2023. Upon funding of the Notes, the warrants meet the accounting criteria to be considered in-substance common stock, and are accounted for as part of the equity-method investment. Refer to Note 6 Investment. The Note Purchase Agreement may be amended with the approval of holders of at least 66 2∕3% of the Notes, except with respect to certain rights that require approval of all holders to amend. Upon an event of default under the Note Purchase Agreement, each purchaser may accelerate the payment of its own Notes. Enforcement against the collateral securing the Notes requires the approval of certain holders as specified in the Notes. SGLT The Company supplies SGLT with certain water-soluble organic compounds required in the Company's proprietary gas fermentation process, small-size equipment and consulting services. As a result, for the three months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $0 and $87, respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized revenue of approximately $75 and $151, respectively. The Company also provided engineering services and incurred costs of $199 and $630 for the three months ended September 30, 2023 and 2022, respectively, and provided engineering services and incurred costs of $612 and $893 for the nine months ended September 30, 2023 and 2022, respectively. Additionally, LanzaTech and SGLT entered into a license agreement in 2019, subsequently amended in August 2023, to provide SGLT with the right to sublicense the intellectual property that LanzaTech previously licensed to

Redeemable, Convertible Preferr

Redeemable, Convertible Preferred Stock	9 Months Ended
Redeemable, Convertible Preferred Stock	Sep. 30, 2023
Temporary Equity Disclosure [Abstract]
Redeemable, Convertible Preferred Stock	Redeemable, Convertible Preferred Stock Prior to the Business Combination, the Company had six outstanding series of contingently redeemable convertible preferred stock. The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts): Shares Authorized Shares Issue Price Carrying Series A 20,414,445 20,414,445 $0.40 - $0.90 $ 12,230 Series B 7,582,934 7,582,934 2.37 18,000 Series C 18,613,084 18,121,698 3.36 60,850 Series D 44,946,572 44,452,681 4.56 188,402 Series E 22,678,139 22,678,139 5.23 118,076 Series F 15,898,496 15,898,496 5.23 83,073 130,133,670 129,148,393 $ 480,631 All redeemable, convertible preferred stock was converted into common shares on the Closing Date of the Business Combination on a 1:1 basis. Immediately before the conversion, all cumulative dividends were declared, totaling a dividend payable of $241,529. This dividend was paid in-kind and subsequently converted, as a result of the Business Combination, into an additional 24,152,942 common shares. After the in-kind dividend payment and the conversion, the former preferred shareholders held 153,895,644 common shares. Prior to the Business Combination, redemption features of the preferred shares were not fixed and did not have a determinable price on fixed or determinable dates. As of December 31, 2022, the preferred shares were not currently redeemable, and it was not probable that the preferred shares would become redeemable, since it was uncertain whether or when circumstances exist that would constitute a deemed liquidation event. Accordingly, the Company did not adjust the carrying value of the preferred shares to their redemption values.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company may be involved in legal proceedings and exposed to potential claims in the normal course of business. As of September 30, 2023 and December 31, 2022, the Company does not have any reasonably possible or probable losses from such claims. Commitments

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net income (loss)	$ (25,326)	$ (26,786)	$ (63,312)	$ (22,267)	$ (15,929)	$ (16,778)	$ (115,424)	$ (54,974)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in Legacy LanzaTech's Annual Report for the year ended December 31, 2022 included in the Company’s prospectus filed with the SEC on May 25, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of Legacy LanzaTech with the acquisition being treated as the equivalent of Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Legacy LanzaTech was deemed to be the predecessor, and the consolidated assets and liabilities and results of operations prior to February 8, 2023 are those of Legacy LanzaTech. Reported shares and earnings per share available to common stockholders, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Merger Agreement. The number of shares of preferred stock was also retroactively restated based on the exchange ratio.
Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles for interim financial information, and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("US GAAP"), the accounting principles, standards, and procedures adopted by the U.S. Securities and Exchange Commission, for complete financial statements. However, in the opinion of management, all adjustments (consisting of normal recurring accruals) have been made that are necessary for a fair presentation of the condensed consolidated financial statements for the interim periods. For further information refer to the Consolidated Financial Statements and Footnotes thereto included in Legacy LanzaTech's Annual Report for the year ended December 31, 2022 included in the Company’s prospectus filed with the SEC on May 25, 2023. The Business Combination is accounted for as a reverse recapitalization as Legacy LanzaTech was determined to be the accounting acquirer under Accounting Standards Codification (“ASC”) 805, Business Combinations (“ASC 805”) based on the evaluation of the following facts and circumstances: • Legacy LanzaTech stockholders have the largest portion of voting rights (85.3% at the closing of the Business Combination) in the Company; • Legacy LanzaTech’s existing senior management team comprise senior management of the Company; • The operations of the Company primarily represent operations of Legacy LanzaTech; and • In comparison with AMCI, Legacy LanzaTech has significantly more revenue and total assets. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of Legacy LanzaTech with the acquisition being treated as the equivalent of Legacy LanzaTech issuing stock for the net assets of AMCI, accompanied by a recapitalization. The net assets of AMCI were stated at historical cost, with no goodwill or other intangible assets recorded. Legacy LanzaTech was deemed to be the predecessor, and the consolidated assets and liabilities and results of operations prior to February 8, 2023 are those of Legacy LanzaTech. Reported shares and earnings per share available to common stockholders, prior to the Business Combination, have been retroactively restated to reflect the exchange ratio established in the Merger Agreement. The number of shares of preferred stock was also retroactively restated based on the exchange ratio.
Variable Interest Entity (“VIE”)	Variable Interest Entity (“VIE”) The Company makes judgments in determining whether an entity is a VIE and, if so, whether it is the primary beneficiary of the VIE and is thus required to consolidate the entity. A VIE is a legal entity that has a total equity investment that is insufficient to finance its activities without additional subordinated financial support or whose equity investors lack the characteristics of a controlling financial interest. The Company’s variable interest arises from contractual, ownership or other monetary interests in the entity, which changes with fluctuations in the fair value of the entity’s net assets. A VIE is consolidated by its primary beneficiary, the party that has both the power to direct the activities that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. The Company consolidates a VIE when the Company is deemed to be the primary beneficiary. The Company assesses whether or not the Company is the primary beneficiary of a VIE on an ongoing basis. If the Company is not deemed to be the primary beneficiary in a VIE, the Company accounts for the investment or other variable interests in a VIE in accordance with applicable US GAAP. The Company holds interests in certain VIEs for which it has been determined the Company is not the primary beneficiary. The Company's variable interests primarily relate to entities in which the Company has a non-controlling equity interest. Although these financial arrangements resulted in holding variable interests in these entities, they do not empower the Company to direct the activities of the VIEs that most significantly impact the VIEs' economic performance. The Company's interests in the VIEs are, therefore, accounted for under the equity method of accounting or at fair value (including, when applicable, the practicability exception to fair value under ASC 321-10-35). Refer to Note 6 - Investments
Going Concern	Going ConcernThe accompanying condensed consolidated financial statements of the Company have been prepared in accordance with US GAAP and assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include fair value of equity awards granted to both employees and non-employees, revenue recognized over time, AM SAFE, Brookfield SAFE, AM SAFE warrants, the Forward Purchase Agreement and the Private Placement Warrants. The Company uses the percentage of completion for both input and output methods to recognize revenue over time for certain contracts with customers. Under the output method, the Company exercises judgment and estimation when determining the percentage of completion against the total transaction price initially estimated. Under the input method, the Company exercises judgment and estimation when selecting the most indicative measure of such performance. Most of our arrangements provide fixed consideration, however, when there are variable consideration elements, the Company estimates the transaction price and whether revenue should be constrained. Significant estimates and judgments are also used when a material right is provided to the customer. In these instances, the Company estimates the stand-alone selling price and apportions the total transaction price to this material right. Refer to the Revenue Recognition section in Note 2 hereunder. Changes in facts and circumstances or additional information may result in revised estimates, and actual results may differ from these estimates.
Segment Information	Segment Information The Company operates as one operating segment. Operating segments are defined as components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker (“CODM”), in deciding how to allocate resources and assess performance. While the Company offers a variety of services and operates in multiple countries, the Company’s business operates in one operating segment because most of the Company’s service offerings are delivered and supported on a global basis, most of the Company’s service offerings are deployed in a similar way, and the Company’s CODM evaluates the Company’s financial information and resources and assesses the performance of these resources on a consolidated basis. There are no segment managers who are held accountable by the CODM, or anyone else, for operations, operating results, and planning for components below the consolidated level. Accordingly, the Company has determined that it has a single reportable and operating segment. See Note 5 - Revenues , for disaggregation of the Company’s revenues by customer location and contract type.
Foreign Currencies	Foreign Currencies The Company’s reporting currency is the U.S. Dollar. The Company has certain foreign subsidiaries where the functional currency is the local currency. All of the assets and liabilities of these subsidiaries are translated to U.S. dollars at the exchange rate in effect at the balance sheet date, income and expense accounts are translated at average rates for the period, and shareholders’ equity accounts are translated at historical rates. The effects of translating financial statements of foreign operations into the Company’s reporting currency are recognized in accumulated other comprehensive income. The Company also has foreign subsidiaries that have a functional currency of the U.S. dollar. Purchases and sales of assets and income and expense items denominated in foreign currencies are remeasured into U.S. dollar amounts on the respective dates of such transactions. Net realized and unrealized foreign currency gains or losses relating to the differences between these recorded amounts and the U.S. dollar equivalent actually received or paid are included within other expense, net in the condensed consolidated statements of operations and comprehensive loss.
Cash and Cash Equivalents, Restricted Cash	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. As of September 30, 2023 and December 31, 2022 , the Company had $91,397 and $83,045 of cash and cash equivalents, respectively. Restricted Cash
Trade and Other Receivables	Trade and Other Receivables Receivables are reported net of allowances for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The Company estimates the allowance for doubtful accounts based on a variety of factors including the length of time receivables are past due, the financial health of customers, unusual macroeconomic conditions, and historical experience.
Investment securities	Investment securities The Company classifies investment securities according to their purpose and holding period. All investment securities are debt securities that have been classified as held-to-maturity (“HTM”) because the Company has both the ability and intent to hold the securities to maturity. HTM debt securities are comprised of U.S. Treasury bills, U.S. Treasury notes, Yankee bonds, and corporate debt. HTM debt securities are carried at amortized cost, which is original cost net of periodic principal repayments and amortization of premiums and accretion of discounts. Accrued interest receivable is recorded within trade and other receivables, net of allowance on the condensed consolidated balance sheets. Amortization of premiums and accretion of discounts are computed using the contractual level-yield method (contractual interest method), adjusted for actual prepayments. The contractual interest method recognizes the income effects of premiums and discounts over the contractual life of the securities based on the actual behavior of the underlying assets, including adjustments for actual prepayment activities, and reflects the contractual terms of the securities without regard to changes in estimated prepayments based on assumptions about future borrower behavior.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity (“ASC 815-40”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815-40, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification.
Forward Purchase Agreement	Forward Purchase Agreement On February 3, 2023, the Company entered into a Forward Purchase Agreement (“FPA”) with ACM . On the same date, ACM partially assigned its rights under the FPA to Vellar. ACM and Vellar are together referred to as the “Purchasers”. Pursuant to the Forward Purchase Agreement, the Purchasers obtained 5,916,514 common shares (“Recycled Shares”) on the open market for $10.16 per share (“Redemption Price”), and such purchase price of $60,096 was funded by the use of AMCI trust account proceeds as a prepayment (“Prepayment Amount”) for the Forward Purchase Agreement redemption 3 years from the date of the Business Combination (“Maturity Date”). The Maturity Date may be accelerated, at the Purchasers discretion, if the Company share price trades below $3.00 per share for any 50 trading days during a 60 day consecutive trading-day period or the Company is delisted. On any date following the Business Combination, the Purchasers also have the option to early terminate the arrangement in whole or in part by providing optional early termination notice to the Company (the “Optional Early Termination”). For those shares early terminated (the “Terminated Shares”), the Purchasers will owe the Company an amount equal to the Terminated Shares times the Redemption Price, which may be reduced in the case of certain dilutive events (“Reset Price”). At the Maturity Date, the Company is obligated to pay the Purchasers an amount equal to the product of (1) 7,500,000 less (b) the number of Terminated Shares multiplied by (2) $2.00 (the “Maturity Consideration”). In addition to the Maturity Consideration, on the Maturity Date, the Company shall pay to the Purchasers an amount equal to the product of (x) 500,000 and (y) the Redemption Price, totaling $5,079 (the “Share Consideration”). If the Purchasers were to utilize their Optional Early Termination to terminate the FPA early, neither the Maturity Consideration nor the Share Consideration would be due to the Purchasers. The Purchasers’ Optional Early Termination economically results in the prepaid forward contract being akin to an in-substance written put option with the Purchaser’s right to sell all or a portion of the 5,916,514 common shares to the Company. The Company is entitled over the 36-month maturity period to either a return of the prepayment or the underlying shares, which the Purchasers will determine at their sole discretion. The FPA consists of three freestanding financial instruments compromising the in-substance written put option (“FPA Put Option”), the minimum portion of the Maturity Consideration (the “Minimum Maturity Consideration”), and the Share Consideration. The FPA Put Option is a derivative instrument the Company has recorded as a liability and measured at fair value. The difference between the initial value of the derivative, including Maturity Consideration in excess of the Minimum Maturity Consideration (the “Variable Maturity Consideration”), and the Prepayment Amount was recorded in the condensed consolidated statement of operations and comprehensive loss. Subsequent changes in fair value of the derivative liability are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss. The Prepayment Amount was accounted for as a reduction to equity to reflect the substance of the overall arrangement as a net repurchase of the Recycled Shares. The Minimum Maturity Consideration, representing 7,500,000 less 5,916,513 multiplied by $2.00 or $3,167, and the Share Consideration are considered to be free-standing debt instruments. The Company has elected to measure these using the Fair Value Option (“FVO”) under ASC 825, Financial Instruments (“ASC 825”). As both the Minimum Maturity Consideration and the Share Consideration will be paid on the same terms and at the same time, these are accounted for together and referred to as the “Fixed Maturity Consideration”. The Variable Maturity Consideration is captured as part of the in-substance written put derivative liability (the FPA Put Option), as noted above. The Fixed Maturity Consideration is recorded as long-term liability on the condensed consolidated balance sheets. The initial value of the Fixed Maturity Consideration is recorded through the condensed consolidated statement of operations and comprehensive loss. Subsequent changes in fair value of the Fixed Maturity Consideration are also recorded in other expense, net on the condensed consolidated statement of operations and comprehensive loss. Prior to filing these financial statements on Form 10-Q, we determined that our prior interpretation of the accounting guidance applicable to certain elements of the Forward Purchase Agreement (“FPA”) was incorrect. As a result, we have revised the accounting treatment of the FPA in our financial statements as of September 30, 2023 to reclassify the Prepayment Amount of $60.5 million, previously recorded as part of a net non-current derivative asset in the condensed consolidated balance sheet, to the equity section of the condensed consolidated balance sheet. The remaining liability balance of $38.1 million associated with the FPA, including the Minimum Maturity Consideration and the Share Consideration, are now reflected as non-current liabilities in our condensed consolidated balance sheet.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company primarily earns revenue from services related to biorefining (formerly known as carbon capture and transformation) which includes feasibility studies and basic engineering design of commercial plants, licensing of technologies and sales of biocatalysts. The other two revenue streams are: (1) joint development and contract research activities to develop and optimize novel biocatalysts, related processes and technologies, and (2) supply of chemical building blocks for sustainable products produced using the Company’s proprietary technologies (referred to as CarbonSmart). Revenue is measured based on the consideration specified in a contract with a customer. The Company records taxes collected from customers and remitted to governmental authorities on a net basis. The Company’s payment terms are between 30-60 days and can vary by customer type and products offered. Management has evaluated the terms of the Company’s arrangements and determined that they do not contain significant financing components. Biorefining The Company provides feasibility studies and basic design and engineering services used for detailed design, procurement, and construction of commercial plants that utilize the Company’s technologies, along with the sale of microbes and media. The services provided are recognized as a performance obligation satisfied over time. Revenue is recognized using the output method based on milestone completion, the cost-to-cost input method for certain engineering services, or the percentage of completion method as performance obligations are satisfied. Revenue for the sale of microbes and media is at a point in time, depending on when control transfers to the customer. The Company licenses intellectual property to generate recurring revenue, in the case of running royalties, or one-time revenue, in the case of fixed consideration royalties, when its customers deploy the Company’s technology in their biorefining plants. When licenses are considered to be distinct performance obligations, the recognition of revenue is dependent on the terms of the contract, which may include fixed consideration or royalties based on sales or usage, in which case the revenue is recognized when the subsequent sale or usage occurs or when the performance obligation to which some or all of the sales or usage-based royalty is allocated has been satisfied, whichever is later. Joint Development and Contract Research The Company performs R&D services related to novel technologies and development of biocatalysts for commercial applications, mainly to produce fuels and chemicals. The Company engages in two main types of R&D services – joint development agreements, and contract research, including projects with the U.S. Department of Energy and other US and foreign government agencies. Such services are recognized as a performance obligation satisfied over time. Revenue is recognized based on milestone completion, when payments are contingent upon the achievement of such milestones, or based on percentage-completion method when enforceable rights to payment exist. When no milestones or phases are clearly defined, management has determined that the cost incurred, input method, is an appropriate measure of progress towards complete satisfaction of the performance obligations under ASC 606 , and estimates its variable consideration under the expected value method. Revenue is not recognized in advance of customer acceptance of a milestone when such acceptance is contractually required. Payments for R&D services with no contractual payments are not due from customers until a technical report is submitted; therefore, a contract asset is recognized at milestone completion but prior to the submission of a technical report. The contract asset represents the Company’s right to consideration for the services performed at milestone completion. Occasionally, customers provide payments in advance of the Company providing services which creates a contract liability for the Company. The contract liability represents the Company's obligation to provide services to a customer. CarbonSmart The Company purchases chemical building blocks from the customers who have deployed our proprietary technologies in their biorefining plants and sells them as CarbonSmart products. Revenue is recognized at a point in time when control transfers to our end customer, which varies depending on the shipping terms. The Company acts as the principal in such transactions and accordingly, recognizes revenue and cost of revenues on a gross basis. Amounts received for sales of CarbonSmart products are classified as Revenue from contract with customers - tangible products in the condensed consolidated statements of operations and comprehensive loss. Collaboration Arrangements The Company has certain partnership agreements that are within the scope of ASC 808, Collaborative Arrangements , which provides guidance on the presentation and disclosure of collaborative arrangements. Generally, the classification of the transaction under the collaborative arrangements is determined based on the nature of the contractual terms of the arrangement, along with the nature of the operations of the participants. The Company’s collaborative agreements generally include a provision of R&D services related to novel technologies and biocatalysts. Amounts received for these services are classified as Revenue from collaborative arrangements in the condensed consolidated statements of operations and comprehensive loss. The Company's R&D services are a major part of the Company's ongoing operations and therefore ASC 606 is applied to recognize revenue.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access; Level 2 — Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities; and Level 3 — Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement , approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, except for the warrant liability.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Revenue generated from the Company’s customers outside of the United States for the three months ended September 30, 2023 and 2022 was approximately 75% and 54%, respectively. Revenue generated from the Company’s customers outside of the United States for the nine months ended September 30, 2023 and 2022 was approximately 75% and 61%, respectively.
Stock-Based Compensation	Stock-Based Compensation In exchange for certain employee and director services, compensation is given in the form of equity-based awards. The Company accounts for equity-based compensation in accordance with ASC 718, Compensation – Stock Compensation. Accordingly, equity-classified awards are recorded based on the grant date fair value and expensed over the requisite service period for the respective award. Liability-classified awards are remeasured at the end of each reporting period and expensed based on the percentage of requisite service that has been rendered. The Company’s equity-based awards include stock option awards, restricted stock units, stock-appreciation rights (“SARs”) and restricted stock issued by the Company, which vest based on either time and/or the achievement of certain market or performance conditions. The Company records forfeitures as they occur. Compensation expense is recognized in the Company’s consolidated statements of operations and comprehensive loss, primarily within research and development expenses. For awards with only service conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for the entire award. For awards with market or performance conditions that have a graded vesting schedule, the Company recognizes compensation cost on a straight-line basis over the requisite service period for each tranche of the award.
Recent Accounting Pronouncements	Recently Adopted and Issued Accounting Pronouncements There are no recently adopted or issued accounting pronouncements that are expected to have a material impact on the Company.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2023
Accounting Policies [Abstract]
Schedule of cash and cash equivalents	The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of September 30, 2023 and December 31, 2022. As of September 30, 2023 December 31, 2022 Cash and cash equivalents $ 91,397 $ 83,045 Restricted cash (presented within Other current assets) 673 665 Cash, cash equivalents and restricted cash $ 92,070 $ 83,710
Customer concentration risk	Customers representing 10% or greater of revenue were as follows for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer A 36 % — % 39 % 10 % Customer B 7 % 27 % 8 % 24 % Customer C — % 21 % — % 10 %

Reverse Recapitalization (Table

Reverse Recapitalization (Tables)	9 Months Ended
Reverse Recapitalization (Tables)	Sep. 30, 2023
Reverse Recapitalization [Abstract]
Schedule of reverse recapitalization	The number of shares of Class A common stock issued and outstanding immediately following the consummation of the Business Combination and PIPE financing were: Shares Percentage Legacy LanzaTech shares 167,324,363 85.3 % Public stockholders 10,398,374 5.3 % PIPE shares 18,500,000 9.4 % Total 196,222,737 100 % The following table reconciles the elements of the Business Combination and PIPE financing to the condensed consolidated statement of cash flows: Recapitalization Cash - AMCI trust account 1 $ 64,090 Cash - PIPE financing 155,000 Less: Transaction costs allocated to equity (5,709) Effect of the Business Combination and PIPE financing $ 213,381 __________________ (1) The cash from the AMCI trust account is net of redemptions and the payment of pre-combination AMCI expenses. The following table reconciles the elements of the Business Combination and PIPE financing to the change in additional paid-in capital on the condensed consolidated statement of changes in redeemable convertible preferred stock and shareholders’ equity / deficit: Recapitalization Cash - AMCI trust account $ 64,090 Public Warrants and Private Placement Warrants recorded on the Closing Date (4,624) Cash - PIPE financing 155,000 Conversion of the AM SAFE 29,730 Transaction costs allocated to equity (7,223) $ 236,973 Less: par value of shares held by PIPE investors and public stockholders (3) Total additional paid-in capital from recapitalization $ 236,970

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
Net Loss Per Share (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock (in thousands, except shares and per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Numerator: Net loss for basic and diluted earnings per common share $ (25,326) $ (22,267) $ (115,424) $ (54,974) Unpaid cumulative dividends on preferred stock — (9,748) (4,117) (28,925) Net loss allocated to common shareholders $ (25,326) $ (32,015) $ (119,541) (83,899) Denominator: Weighted-average shares used in calculating net loss per share, basic and diluted 195,869,537 9,229,781 169,797,443 9,223,884 Net loss per common share, basic and diluted (1) $ (0.13) $ (3.47) $ (0.70) $ (9.10) __________________ (1) In periods in which the Company reports a net loss, all common stock equivalents are excluded from the calculation of diluted weighted average shares outstanding because of their anti-dilutive effect on loss per share.
Schedule of antidilutive securities excluded from computation	As of September 30, 2023 and 2022, common stock equivalents not included in the computation of loss per share because their effect would be antidilutive include the following: September 30, 2023 2022 Redeemable convertible preferred stock (if converted) — 129,148,393 Options 17,021,827 16,584,305 RSUs 7,042,901 — RSAs — 2,535,825 Brookfield SAFE 5,000,000 — Warrants 16,657,686 985,278 Total 45,722,414 149,253,801

Revenues (Tables)

Revenues (Tables)	9 Months Ended
Revenues (Tables)	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Disaggregated revenue	The following table presents disaggregated revenue in the following categories (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Contract Types: Licensing $ 1,515 $ 540 $ 2,902 $ 1,620 Engineering and other services 10,912 2,955 25,572 12,630 Biorefining revenue $ 12,427 $ 3,495 $ 28,474 $ 14,250 Joint development agreements 1,933 1,571 5,049 4,018 Contract research 2,987 1,315 5,380 4,100 Joint development and contract research revenue $ 4,920 $ 2,886 $ 10,429 $ 8,118 CarbonSmart (tangible product) 2,258 1,691 3,265 3,413 Total Revenue $ 19,605 $ 8,072 $ 42,168 $ 25,781 The following table presents revenue from partners in collaborative arrangements, which is included in the table above within Joint development agreements (in thousands). Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue from partners in collaborative agreements 1,566 $ 760 3,116 1,733 The following table presents disaggregation of the Company’s revenues by customer location for the three and nine months ended September 30, 2023 and 2022 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 North America $ 4,847 $ 4,412 $ 11,309 $ 12,361 Europe, Middle East, Africa (EMEA) 10,732 1,287 25,088 7,894 Asia 2,137 1,888 2,690 4,151 Australia 1,889 485 3,081 1,375 Total Revenue $ 19,605 $ 8,072 $ 42,168 $ 25,781
Changes in contract assets and liabilities	The following table provides changes in contract assets and liabilities (in thousands): Current Contract Assets Current Contract Liabilities Non-current Contract Liabilities Balance as of January 1, 2023 $ 18,000 $ 3,101 $ 10,760 Additions to unbilled accounts receivable 43,901 — — Increases due to cash received — 4,486 — Unbilled accounts receivable recognized in trade receivables (37,413) — — Decrease on revaluation on currency (175) — (73) Reclassification from long-term to short-term — 2,016 (2,016) Reclassification to revenue as a result of performance obligations satisfied — (6,471) — Balance as of September 30, 2023 $ 24,313 $ 3,132 $ 8,671
Remaining performance obligations	Remaining performance obligations consisted of the following (in thousands): As of September 30, 2023 December 31, 2022 Current $ 3,132 $ 3,101 Non-current 8,671 10,760 Total $ 11,803 $ 13,861

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments	The Company’s equity investments consisted of the following (in thousands): As of September 30, 2023 December 31, 2022 Equity Method Investment in LanzaJet $ 9,594 $ 10,561 Equity Security Investment in SGLT 14,990 14,990 Total Investment $ 24,584 $ 25,551
Debt Securities, Held-to-Maturity	HTM debt securities are classified as short-term or long-term based upon the contractual maturity of the underlying investment. September 30, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Accrued Interest Short-term US Treasury bills and notes $ 20,178 $ — $ (7) $ 20,171 $ 45 Corporate debt securities 14,833 3 (26) 14,810 109 Total debt securities due within a year $ 35,011 $ 3 $ (33) $ 34,981 $ 154 After 1 year through 5 years Corporate debt 6,780 3 (3) 6,780 24 Yankee debt securities 3,000 2 — 3,002 — Total debt securities due after 1 year through 5 years $ 9,780 $ 5 $ (3) $ 9,782 $ 24 Total HTM Debt Securities 44,791 8 (36) 44,763 178

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
Fair Value (Tables)	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of assets and liabilities that are measured at fair value on a recurring basis	The following table presents the Company’s fair value hierarchy for its assets and liabilities measured at fair value as of September 30, 2023 and December 31, 2022 (in thousands): Fair Value Measurement as of September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 37,370 $ — $ — $ 37,370 Total assets $ 37,370 $ — $ — $ 37,370 Liabilities: FPA Put Option liability $ — $ — $ 38,092 $ 38,092 Fixed Maturity Consideration — — 7,020 7,020 Brookfield SAFE liability — — 23,350 23,350 Private placement warrants — — 5,060 5,060 Public warrants 4,575 — — 4,575 Total liabilities $ 4,575 $ — $ 73,522 $ 78,097 Fair Value Measurement as of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 523 $ — $ — $ 523 Liabilities: Warrants on preferred shares — — 2,119 2,119 Brookfield SAFE liability — — 50,000 50,000 AM SAFE warrant — — 1,989 1,989 AM SAFE liability — — 28,986 28,986 Total Liabilities $ — $ — $ 83,094 $ 83,094
Summary of quantitative information regarding Level 3 fair value measurement inputs	The following table represents the weighted average inputs used in calculating the fair value of the prepaid forward contract and the Fixed Maturity Consideration as of September 30, 2023: September 30, 2023 Stock price $ 4.67 Term (in years) 2.36 Expected volatility 50.0 % Risk-free interest rate 4.89 % Expected dividend yield — % December 31, 2022 Stock price $ 5.21 Weighted average exercise price $ 3.96 Term (in years) 1.1 Expected volatility 73.4 % Risk-free interest rate 4.47 % Expected dividend yield — % May 13, 2023 Stock price $ 3.42 Weighted average exercise price $ 10.00 Term (in years) 4.87 Expected volatility 54.0 % Risk-free interest rate 3.46 % Expected dividend yield — % Near Term Long-Term Key assumptions: Probability weighting 61 % 39 % Time to conversion (in years) 0.1 0.8 Liquidity price 100 % 90 % Discount rate 24.7 % 24.7 % At conversion to equity classification on February 8, 2023, the AM SAFE warrant was valued usin g a Black-Scholes option pricing model as the warrant became exercisable for a fixed number of shares at a fixed price as described in Note 7 - Warrants . The following table represents the weighted average inputs used in calculating the fair value of the preferred share warrants outstanding at conversion to equity on February 8, 2023: February 8, 2023 Stock price $ 9.91 Term (in years) 5.00 Expected volatility 70.0 % Risk-free interest rate 3.82 % Expected dividend yield — % Significant inputs for Level 3 AM SAFE warrant fair value measurement at December 31, 2022 are as follows (in thousands): Near Term Long-Term Key assumptions: Probability weighting 61 % 39 % Remaining life (in years) 5.0 5.0 Volatility 75 % 75 % Interest rate 3.99 % 3.99 % Time to conversion (in years) 0.1 0.8 Risk-free interest rate 4.12 % 4.75 % Dividend yield — % — % Significant inputs for Level 3 Brookfield SAFE measurement at September 30, 2023 are as follows: September 30, 2023 Initial purchase amount $ 50,000 Liquidity price $ 10.00 Stock price $ 4.67 The following table represents the weighted average inputs used in calculating the fair value of the Private Placement Warrants outstanding as of September 30, 2023 and at the time of the Business Combination: September 30, 2023 Stock price $ 4.67 Exercise price $ 11.50 Term (in years) 4.36 Expected volatility 52.5 % Risk-free interest rate 4.66 % Expected dividend yield — %
Summary of change in the fair value of the derivative warrant liabilities, measured using Level 3 inputs	The following tables represent reconciliations of the fair value measurements of the assets and liabilities using significant unobservable inputs (Level 3) (in thousands): Fixed Maturity Consideration Shortfall Warrants Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Brookfield SAFE Private placement warrants Balance as of January 1, 2023 $ — $ — $ (2,119) $ (28,986) $ (1,989) $ (50,000) $ — Recognized as a result of the Business Combination — — — — — — (2,148) (Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (7,020) (3,063) (3,770) (744) 189 26,650 (2,912) Conversion of warrants to preferred shares — — 5,889 — — — — Conversion of SAFE liability to equity classification — — — 29,730 — — — Conversion of warrant to equity classification — 3,063 — — 1,800 — — Balance as of September 30, 2023 $ (7,020) $ — $ — $ — $ — $ (23,350) $ (5,060) Warrants on Preferred Shares AM SAFE liability AM SAFE warrant Balance as of January 1, 2022 $ (1,145) $ (28,271) $ (1,729) Gain (loss) recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss (427) 1,050 (293) Balance as of September 30, 2022 $ (1,572) $ (27,221) $ (2,022)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
Share-Based Compensation (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Restricted stock units activity	A summary of the unvested time-based and market-based equity-classified RSUs are presented in the following table: Number of RSUs (thousands) Weighted Average Grant Date Fair Value Time-based Market-based January 1, 2023 — — $ — Granted 3,143 3,930 2.49 Vested (2) — 3.45 Cancelled/forfeited (28) — 3.43 September 30, 2023 3,113 3,930 $ 2.49
Stock options activity	Stock option awards outstanding as of September 30, 2023 and changes during the period ended September 30, 2023 were as follows: Shares subject to option (thousands) Weighted average exercise price Weighted average remaining contractual term (years) Aggregate intrinsic value (thousands) Outstanding at January 1, 2023 14,661 $ 1.48 5.80 Vested and expecting to vest at January 1, 2023 14,661 1.48 5.80 Exercisable at January 1, 2023 11,203 $ 1.44 5.15 Granted 3,556 3.77 — Exercised (1,075) 1.53 — Cancelled/forfeited (120) 1.76 — Outstanding at September 30, 2023 17,022 $ 1.95 6.21 $ 47,653 Vested and expecting to vest at September 30, 2023 17,022 1.95 6.21 47,653 Exercisable at September 30, 2023 11,208 $ 1.48 4.98 $ 36,026

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
Related Party Transactions (Tables)	Sep. 30, 2023
Related Party Transactions [Abstract]
Amounts related to transactions with related parties	The table below summarizes amounts related to transactions with these related parties (in thousands) : As of September 30, 2023 December 31, 2022 Accounts receivable $ 763 $ 1,821 Notes receivable 5,351 — Accounts payable 635 3,195 The following table presents revenue from related parties per disaggregated revenue categories: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenue from related parties, included within Licensing 1,515 540 2,902 1,620 Revenue from related parties, included within Engineering and other services 104 164 766 496 The main transactions with related parties are described below:

Redeemable, Convertible Prefe_2

Redeemable, Convertible Preferred Stock (Tables)	9 Months Ended
Redeemable, Convertible Preferred Stock (Tables)	Sep. 30, 2023
Temporary Equity Disclosure [Abstract]
Redeemable convertible preferred stock	The dollar amounts and share counts in the table below are adjusted to reflect the impact of the exchange ratio on the shares authorized, shares issued and outstanding, and issue price. The authorized, issued and outstanding shares, issue price, and carrying value as of December 31, 2022 are as follows (in thousands, except share and per share amounts): Shares Authorized Shares Issue Price Carrying Series A 20,414,445 20,414,445 $0.40 - $0.90 $ 12,230 Series B 7,582,934 7,582,934 2.37 18,000 Series C 18,613,084 18,121,698 3.36 60,850 Series D 44,946,572 44,452,681 4.56 188,402 Series E 22,678,139 22,678,139 5.23 118,076 Series F 15,898,496 15,898,496 5.23 83,073 130,133,670 129,148,393 $ 480,631

Description of the Business (De

Description of the Business (Details) $ in Thousands	Sep. 30, 2023 USD ($) plant	Dec. 31, 2022 USD ($)	Sep. 30, 2022 plant
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to other accrued liabilities	$ (6,049)	$ (4,502)
Warrants	$ 9,636	4,108
China
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Commercial plants operated \| plant	4		3
India
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Commercial plants operated \| plant	1
Reclassification Of Warrants On Preferred Shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to other accrued liabilities		2,119
Warrants		$ 2,119

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Basis of Presentation and Going Concern (Details) - USD ($) $ in Thousands		3 Months Ended						9 Months Ended
	Feb. 08, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Accounting Policies [Abstract]
Voting rights stock held	85.30%
Cash and cash equivalents		$ 91,397						$ 91,397		$ 83,045
Held-to-maturity securities		44,791						44,791
Accumulated deficit		(813,198)						(813,198)		$ (456,245)
Net cash used in operating activities								(81,565)	$ (71,336)
Net income (loss)		$ (25,326)	$ (26,786)	$ (63,312)	$ (22,267)	$ (15,929)	$ (16,778)	$ (115,424)	$ (54,974)
Proceeds from divestiture of businesses, net	$ 153,285

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Segment Information (Details)	9 Months Ended
	Sep. 30, 2023 segment
Accounting Policies [Abstract]
Number of operating segments	1

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 91,397	$ 83,045

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash Reconciliation (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 91,397	$ 83,045
Restricted Cash	673	665
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total	$ 92,070	$ 83,710	$ 51,034	$ 128,732

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Trade and Other Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 1,751	$ 1,051

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Forward Purchase Agreement (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 shares	Feb. 03, 2023 USD ($) consecutiveTradingDay tradingDay financial_instrument $ / shares shares	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares	196,222,737
Trigger share price (usd per share) \| $ / shares		$ 3
Number of freestanding financial instruments \| financial_instrument		3
Trading days \| tradingDay		50
Consecutive trading days \| consecutiveTradingDay		60
Additional paid-in capital			$ 939,868	$ 24,782
FPA Put Option liability			38,092	$ 0
Revision of Prior Period, Adjustment
Derivative [Line Items]
Derivative asset, noncurrent			60,500
Additional paid-in capital			60,500
FPA Put Option liability			$ 38,100
Forward Contracts
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares		5,916,514
Sale of stock price (usd per share) \| $ / shares		$ 10.16
Purchase price		$ 60,096
Derivative term		3 years
Forward Contracts \| Maturity Consideration
Derivative [Line Items]
Maturity consideration, amount		$ 5,079
Maturity consideration (in shares) \| shares		500,000
Maturity consideration (usd per share) \| $ / shares		$ 2
Shares to issue (in shares) \| shares		7,500,000
Forward Contracts \| Fixed Maturity Consideration
Derivative [Line Items]
Shares issued in transaction (in shares) \| shares		5,916,513
Maturity consideration, amount		$ 3,167
Maturity consideration (usd per share) \| $ / shares		$ 2
Shares to issue (in shares) \| shares		7,500,000

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Concentration of Credit Risk and Other Risks and Uncertainties (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue Benchmark \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage	75%	54%	75%	61%
Revenue Benchmark \| Customer Concentration Risk \| Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	36%	0%	39%	10%
Revenue Benchmark \| Customer Concentration Risk \| Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	7%	27%	8%	24%
Revenue Benchmark \| Customer Concentration Risk \| Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	0%	21%	0%	10%
Accounts Receivable \| Geographic Concentration Risk \| Non-US
Concentration Risk [Line Items]
Concentration risk, percentage			49%		35%

Reverse Recapitalization - Narr

Reverse Recapitalization - Narrative (Details) $ / shares in Units, $ in Thousands	Feb. 08, 2023 USD ($) $ / shares shares	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Schedule Of Reverse Recapitalization [Line Items]
Common shares, shares authorized (in shares)	196,222,737	400,000,000	158,918,093
Common shares, par value (in dollars per share) \| $ / shares	$ 0.0001	$ 0.0001	$ 0.0001
Warrants outstanding (in shares)	12,574,200
Recapitalization exchange ratio	4.3747
Shares issued in transaction (in shares)	196,222,737
Recapitalization costs \| $	$ 7,223
Priced At $10.00 Per Share
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	15,500,000
Stock repurchased (usd per share) \| $ / shares	$ 10
AMCI
Schedule Of Reverse Recapitalization [Line Items]
Stock repurchased (in shares)	8,351,626
Stock repurchased (usd per share) \| $ / shares	$ 10.16
Public stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
PIPE shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
AM SAFE Liability
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	3,000,000

Reverse Recapitalization - Sche

Reverse Recapitalization - Schedule of Shares (Details)	Feb. 08, 2023 shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	196,222,737
Percentage	100%
Legacy LanzaTech shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	167,324,363
Percentage	85.30%
Public stockholders
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	10,398,374
Percentage	5.30%
PIPE shares
Schedule Of Reverse Recapitalization [Line Items]
Shares issued in transaction (in shares)	18,500,000
Percentage	9.40%

Reverse Recapitalization - Cash

Reverse Recapitalization - Cash Flow Reconciliation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Reverse Recapitalization [Abstract]
Cash - AMCI trust account	$ 64,090
Public Warrants and Private Placement Warrants recorded on the Closing Date	(4,624)
Cash - PIPE financing	155,000
Conversion of the AM SAFE	29,730
Transaction costs allocated to equity	(7,223)
Proceeds From Reverse Recapitalization Transaction	236,973
Less: Transaction costs allocated to equity	(5,709)
Less: par value of shares held by PIPE investors and public stockholders	(3)
Effect of the Business Combination and PIPE financing	213,381
Total additional paid-in capital from recapitalization	$ 236,970

Net Loss Per Share - Narrative

Net Loss Per Share - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
Net Loss Per Share - Narrative (Details) $ in Thousands	Feb. 08, 2023 USD ($) denominator shares	Feb. 07, 2023 shares	Mar. 31, 2023 USD ($)	Sep. 30, 2023 shares	Sep. 30, 2022 shares
Earnings Per Share [Abstract]
Recapitalization exchange ratio	4.3747
In-kind payment of preferred dividend \| $	$ 241,529		$ 241,529
Conversion ratio	1
Dividends, denominator \| denominator	10
Common stock dividends (in shares)	24,152,942
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Aggregate purchase of stock (in shares)				45,722,414	149,253,801
Redeemable convertible preferred stock (if converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Aggregate purchase of stock (in shares)		129,148,393		0	129,148,393

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Calculation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net loss for basic and diluted earnings per common share	$ (25,326)	$ (26,786)	$ (63,312)	$ (22,267)	$ (15,929)	$ (16,778)	$ (115,424)	$ (54,974)
Unpaid cumulative dividends on preferred stock	0			(9,748)			(4,117)	(28,925)
Net loss allocated to common shareholders	$ (25,326)			$ (32,015)			$ (119,541)	$ (83,899)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average shares used in calculating net loss per share, basic (in shares)	195,869,537			9,229,781			169,797,443	9,223,884
Weighted-average shares used in calculating net loss per share, diluted (in shares)	195,869,537			9,229,781			169,797,443	9,223,884
Net loss per common share, basic (in dollars per share)	$ (0.13)			$ (3.47)			$ (0.70)	$ (9.10)
Net loss per common share, diluted (in dollars per share)	$ (0.13)			$ (3.47)			$ (0.70)	$ (9.10)

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Shares (Details) - shares	1 Months Ended	9 Months Ended
Net Loss Per Share - Antidilutive Shares (Details) - shares	Feb. 07, 2023	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		45,722,414	149,253,801
Redeemable convertible preferred stock (if converted)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	129,148,393	0	129,148,393
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		17,021,827	16,584,305
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		7,042,901	0
RSAs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		0	2,535,825
Brookfield SAFE
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		5,000,000	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares		16,657,686	985,278

Revenues - Disaggregated Revenu

Revenues - Disaggregated Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 19,605	$ 8,072	$ 42,168	$ 25,781
Revenue from collaborative arrangements	1,566	760	3,116	1,733
Biorefining revenue
Disaggregation of Revenue [Line Items]
Revenues	12,427	3,495	28,474	14,250
Licensing
Disaggregation of Revenue [Line Items]
Revenues	1,515	540	2,902	1,620
Engineering and other services
Disaggregation of Revenue [Line Items]
Revenues	10,912	2,955	25,572	12,630
Research and development
Disaggregation of Revenue [Line Items]
Revenues	4,920	2,886	10,429	8,118
Joint development agreements
Disaggregation of Revenue [Line Items]
Revenues	1,933	1,571	5,049	4,018
Contract research
Disaggregation of Revenue [Line Items]
Revenues	2,987	1,315	5,380	4,100
CarbonSmart (tangible product)
Disaggregation of Revenue [Line Items]
Revenues	2,258	1,691	3,265	3,413
Related Party \| Licensing
Disaggregation of Revenue [Line Items]
Revenues	1,515	540	2,902	1,620
Related Party \| Engineering and other services
Disaggregation of Revenue [Line Items]
Revenues	$ 104	$ 164	$ 766	$ 496

Revenues - Disaggregation by Cu

Revenues - Disaggregation by Customer Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenues	$ 19,605	$ 8,072	$ 42,168	$ 25,781
North America
Disaggregation of Revenue [Line Items]
Revenues	4,847	4,412	11,309	12,361
Europe, Middle East, Africa (EMEA)
Disaggregation of Revenue [Line Items]
Revenues	10,732	1,287	25,088	7,894
Asia
Disaggregation of Revenue [Line Items]
Revenues	2,137	1,888	2,690	4,151
Australia
Disaggregation of Revenue [Line Items]
Revenues	$ 1,889	$ 485	$ 3,081	$ 1,375

Revenues - Contract Balances (D

Revenues - Contract Balances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Contract with Customer, Asset, after Allowance for Credit Loss, Current [Abstract]
Beginning balance	$ 18,000
Additions to unbilled accounts receivable	43,901
Unbilled accounts receivable recognized in trade receivables	(37,413)
Decrease on revaluation on currency	(175)
Ending balance	24,313
Contract With Customer, Liability, Current [Abstract]
Beginning balance	3,101
Increases due to cash received		$ 4,486
Reclassification from long-term to short-term	2,016
Reclassification to revenue as a result of performance obligations satisfied	(6,471)
Ending balance	3,132
Contract With Customer, Liability, Noncurrent [Abstract]
Beginning balance	10,760
Decrease on revaluation on currency	(73)
Reclassification from long-term to short-term	(2,016)
Ending balance	$ 8,671

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Billed accounts receivable, net of allowance	$ 10,085	$ 11,695

Revenues - Remaining Performanc

Revenues - Remaining Performance Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Current	$ 3,132	$ 3,101
Non-current	8,671	10,760
Total	$ 11,803	$ 13,861

Investments - Held to Maturity

Investments - Held to Maturity Securities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	$ 35,011
Gross Unrealized Gains	3
Gross Unrealized Losses	(33)
Estimated Fair Value	34,981
Accrued Interest	154
Amortized Cost	9,780
Gross Unrealized Gains	5
Gross Unrealized Losses	(3)
Estimated Fair Value	9,782
Accrued Interest	24
Amortized Cost	44,791
Gross Unrealized Gains	8
Gross Unrealized Losses	(36)
Estimated Fair Value	44,763
Accrued Interest	178
US Treasury Bills and Notes
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	20,178
Gross Unrealized Gains	0
Gross Unrealized Losses	(7)
Estimated Fair Value	20,171
Accrued Interest	45
Corporate Debt Securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	14,833
Gross Unrealized Gains	3
Gross Unrealized Losses	(26)
Estimated Fair Value	14,810
Accrued Interest	109
Amortized Cost	6,780
Gross Unrealized Gains	3
Gross Unrealized Losses	(3)
Estimated Fair Value	6,780
Accrued Interest	24
Yankee Debt Securities
Schedule of Held-to-Maturity Securities [Line Items]
Amortized Cost	3,000
Gross Unrealized Gains	2
Gross Unrealized Losses	0
Estimated Fair Value	3,002
Accrued Interest	$ 0

Investments - Narrative (Detail

Investments - Narrative (Details) $ / shares in Units, ¥ in Thousands				2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 13, 2020 USD ($)	Sep. 28, 2011 USD ($)	Sep. 28, 2011 CNY (¥)	Apr. 04, 2021 USD ($) investment_round shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Feb. 08, 2023 $ / shares	Nov. 09, 2022 $ / shares
Schedule of Equity Method Investments [Line Items]
Allowance for credit losses related to held-to-maturity securities					$ 0		$ 0
Number of rounds of investments \| investment_round				2
Class of warrant or right, exercise price of warrants or rights (in dollars per share) \| $ / shares										$ 9.91	$ 0.01
Equity method investments cost							288,000	$ 0
Impairment on equity method investments							0		$ 0
Dividends from equity investments					$ 0	$ 0	$ 0	0
LanzaJet
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property	$ 15,000,000
Ownership percentage	37.50%			25%	23.15%		23.15%
Revenue					$ 565,000	540,000	$ 1,701,000
Deferred revenue					$ 6,047,000		$ 6,047,000		8,062,000
Profit amortization period							15 years
Gain from equity method investment							$ 502,000
Ownership if diluted					22.38%		22.38%
Contingent right to receive additional interest \| shares				45,000,000
Equity method investments cost				$ 0
Carrying value less than proportionate share of book value					$ 2,200,000		$ 2,200,000		$ 3,700,000
LanzaJet \| Intra-entity
Schedule of Equity Method Investments [Line Items]
Revenue					$ 107,000	$ 132,000	$ 313,000	$ 395,000
SGLT
Schedule of Equity Method Investments [Line Items]
Ownership percentage		30%	30%						9.31%
SGLT \| Intellectual Property
Schedule of Equity Method Investments [Line Items]
Contribution of intellectual property		$ 4,000,000	¥ 25,800

Investments - Equity Method Inv

Investments - Equity Method Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment in LanzaJet	$ 9,594	$ 10,561
Equity Security Investment in SGLT	14,990	14,990
Total Investment	$ 24,584	$ 25,551

Warrants (Details)

Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	9 Months Ended
	May 13, 2023	Feb. 08, 2023	Mar. 31, 2023	Sep. 30, 2023	Mar. 27, 2023	Nov. 09, 2022
Warrants
Number of shares issuable by warrant (in shares)		985,278				316,250
Exercise of warrants (in shares)		594,309	594,309
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 9.91				$ 0.01
Fair value of shares		$ 5,890
Warrants outstanding (in shares)		12,574,200
Minimum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 3.36
Maximum
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		4.56
AM SAFE Warrant
Warrants
Number of shares issuable by warrant (in shares)				300,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 10		$ 10
Fair value of shares				$ 1,800
Shortfall Warrants
Warrants
Fair value of shares	$ 3,063
Price of warrant (in usd per warrant)					$ 10
Gain on reclassification	$ 2,042
Shortfall Warrants \| ACM
Warrants
Warrants issued (in shares)					2,073,486
Shortfall Warrants \| Vellar Opportunity Fund SPV LLC - Series 10
Warrants
Warrants issued (in shares)					2,010,000
Public Warrants and Private Placement Warrants
Warrants
Class of warrant or right, exercise price of warrants or rights (in dollars per share)				$ 11.50
Price of warrant (in usd per warrant)				$ 11.50
Threshold period days after the completion of the initial Business Combination for exercise of warrants				30 days
Public Warrants and Private Placement Warrants \| Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00
Warrants
Redemption price per public warrant (in dollars per share)				$ 0.01
Redemption period				30 days
Trigger price (usd per share)				$ 18
Threshold trading days for redemption of public warrants				20 days
Minimum threshold written notice period for redemption of public warrants				30 days
Public warrants
Warrants
Warrants outstanding (in shares)		7,499,924		7,499,924
Private placement warrants
Warrants
Warrants outstanding (in shares)		4,774,276		4,774,276

Forward Purchase Agreement - Na

Forward Purchase Agreement - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Derivative [Line Items]
FPA Put Option liability	$ 38,092	$ 0
Fixed Maturity Consideration	7,020	$ 0
Forward Contracts
Derivative [Line Items]
Derivative transaction costs	$ 451

Fair Value - Financial Assets a

Fair Value - Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Liabilities:
Warrants	$ 9,636	$ 4,108
Brookfield SAFE liability		50,000
AM SAFE liability	0	28,986
Fair Value, Recurring
Assets:
Cash equivalents	37,370	523
Total assets	37,370
Liabilities:
FPA Put Option liability	38,092
Fixed Maturity Consideration	7,020
Warrants		2,119
Brookfield SAFE liability	23,350	50,000
AM SAFE liability		28,986
Total liabilities	78,097	83,094
Fair Value, Recurring \| Private placement warrants
Liabilities:
Warrants	5,060
Fair Value, Recurring \| Public warrants
Liabilities:
Warrants	4,575
Fair Value, Recurring \| AM SAFE warrant
Liabilities:
Warrants		1,989
Fair Value, Recurring \| Level 1
Assets:
Cash equivalents	37,370	523
Total assets	37,370
Liabilities:
FPA Put Option liability	0
Fixed Maturity Consideration	0
Warrants		0
Brookfield SAFE liability	0	0
AM SAFE liability		0
Total liabilities	4,575	0
Fair Value, Recurring \| Level 1 \| Private placement warrants
Liabilities:
Warrants	0
Fair Value, Recurring \| Level 1 \| Public warrants
Liabilities:
Warrants	4,575
Fair Value, Recurring \| Level 1 \| AM SAFE warrant
Liabilities:
Warrants		0
Fair Value, Recurring \| Level 2
Assets:
Cash equivalents	0	0
Total assets	0
Liabilities:
FPA Put Option liability	0
Fixed Maturity Consideration	0
Warrants		0
Brookfield SAFE liability	0	0
AM SAFE liability		0
Total liabilities	0	0
Fair Value, Recurring \| Level 2 \| Private placement warrants
Liabilities:
Warrants	0
Fair Value, Recurring \| Level 2 \| Public warrants
Liabilities:
Warrants	0
Fair Value, Recurring \| Level 2 \| AM SAFE warrant
Liabilities:
Warrants		0
Fair Value, Recurring \| Level 3
Assets:
Cash equivalents	0	0
Total assets	0
Liabilities:
FPA Put Option liability	38,092
Fixed Maturity Consideration	7,020
Warrants		2,119
Brookfield SAFE liability	23,350	50,000
AM SAFE liability		28,986
Total liabilities	73,522	83,094
Fair Value, Recurring \| Level 3 \| Private placement warrants
Liabilities:
Warrants	5,060
Fair Value, Recurring \| Level 3 \| Public warrants
Liabilities:
Warrants	$ 0
Fair Value, Recurring \| Level 3 \| AM SAFE warrant
Liabilities:
Warrants		$ 1,989

Fair Value - Level 3 Fair Value

Fair Value - Level 3 Fair Value Measurements (Details) $ in Thousands	Sep. 30, 2023 USD ($) $ / shares	May 13, 2023 $ / shares	Feb. 08, 2023	Dec. 31, 2022 $ / shares
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	4.67
Warrants, measurement input			9.91	5.21
Brookfield SAFE, measurement input	4.67
Stock price \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		3.42
Stock price \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	4.67
Term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	2.36
Warrants, measurement input			5	1.1
Term (in years) \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		4.87
Term (in years) \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				5
Term (in years) \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				5
Term (in years) \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	4.36
Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0.500
Warrants, measurement input			0.700	0.734
Expected volatility \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		0.540
Expected volatility \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.75
Expected volatility \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.75
Expected volatility \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.525
Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0.0489
Warrants, measurement input			0.0382	0.0447
Risk-free interest rate \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		0.0346
Risk-free interest rate \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.0412
Risk-free interest rate \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.0475
Risk-free interest rate \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0.0466
Expected dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative asset, measurement input	0
Warrants, measurement input			0	0
Expected dividend yield \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		0
Expected dividend yield \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0
Expected dividend yield \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0
Expected dividend yield \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	0
Weighted average exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				3.96
Weighted average exercise price \| Shortfall Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input		10
Weighted average exercise price \| Private placement warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input	11.50
Probability weighting \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.61
Probability weighting \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.39
Probability weighting \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.61
Probability weighting \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.39
Interest rate \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.0399
Interest rate \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.0399
Time to conversion (in years) \| SAFE Warrant, Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.1
Time to conversion (in years) \| SAFE Warrant, Long Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants, measurement input				0.8
Time to conversion (in years) \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.1
Time to conversion (in years) \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.8
Liquidity price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Brookfield SAFE, measurement input	10
Liquidity price \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				1
Liquidity price \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.90
Discount rate \| Near Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.247
Discount rate \| Long-Term
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input				0.247
Initial purchase amount
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Brookfield SAFE, measurement input \| $	50,000

Fair Value - Narrative (Details

Fair Value - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		8 Months Ended	9 Months Ended
	Feb. 08, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Brookfield SAFE liability, fair value					$ 50,000
Brookfield SAFE liability		$ 23,350	$ 23,350		50,000
Warrants
Shares issued in transaction (in shares)	196,222,737
AM SAFE liability		0	0		28,986
Change in fair value of derivative warrant liabilities			$ (14,249)	$ (330)
AM SAFE Liability
Warrants
Shares issued in transaction (in shares)	3,000,000
AM SAFE liability	$ 29,730				$ 28,986
Stock repurchased (usd per share)	$ 9.91
Other Expense \| Public warrants
Warrants
Change in fair value of derivative warrant liabilities		2,100
Other Expense \| Private placement warrants
Warrants
Change in fair value of derivative warrant liabilities		$ 2,912

Fair Value - Change in Fair Val

Fair Value - Change in Fair Value of Derivative Warrant Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Fixed Maturity Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 0
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(7,020)
Ending balance	(7,020)
Shortfall Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(3,063)
Conversion of warrant to equity classification	3,063
Ending balance	0
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(2,119)	$ (1,145)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(3,770)	(427)
Conversion of warrants to preferred shares	5,889
Ending balance	0	(1,572)
AM SAFE liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(28,986)	(28,271)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(744)	1,050
Conversion of SAFE liability to equity classification	29,730
Ending balance	0	(27,221)
AM SAFE warrant
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(1,989)	(1,729)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	189	(293)
Conversion of warrant to equity classification	1,800
Ending balance	0	$ (2,022)
Brookfield SAFE
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	(50,000)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	26,650
Ending balance	(23,350)
Private placement warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
Recognized as a result of the Business Combination	(2,148)
(Loss) gain recognized in other expense, net on the condensed consolidated statement of operations and comprehensive loss	(2,912)
Ending balance	$ (5,060)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes - Narrative (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Foreign earnings repatriated	$ 0	$ 0
Deferred income taxes recognized	0	0	$ 0	$ 0
Income tax expense	$ 0	$ 0	$ 0	$ 0
Effective tax rate	0%	0%

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details)	3 Months Ended		9 Months Ended
Share-Based Compensation - Narrative (Details)	Sep. 30, 2023 USD ($) installment share_type day $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) installment share_type day $ / shares shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock price (usd per share) \| $ / shares	$ 11.50		$ 11.50
Share price threshold trading days			20 days
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of share based stock schemes \| share_type	2		2
Vesting installments \| installment	3		3
Compensation expense	$ 1,895,000		$ 4,594,000
Unrecognized compensation costs	$ 12,936,000		$ 12,936,000
Unrecognized cost, recognition period			1 year 11 months 23 days
Unvested shares weighted average fair value (usd per share) \| $ / shares	$ 2.49		$ 2.49		$ 0
Time Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested shares outstanding (in shares) \| shares	3,113,000		3,113,000		0
Time Based RSU \| Director
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period			1 year
Time Based RSU \| Employees and Other Service Providers
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period			3 years
Market Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period			3 years
Vesting component triggering event \| day	151		151
Unvested shares outstanding (in shares) \| shares	3,930,000		3,930,000		0
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 1,234,000	$ 653,000	$ 4,443,000	$ 2,067,000
Unrecognized compensation costs	9,550,000		$ 9,550,000
Unrecognized cost, recognition period			2 years 3 months 14 days
RSAs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation expense	$ 0	$ 0	$ 2,741,000	$ 0
Unrecognized cost, recognition period			10 years
Award requisite service period			3 years
Unvested shares outstanding (in shares) \| shares					2,535,825
Unvested shares weighted average fair value (usd per share) \| $ / shares	$ 1.08		$ 1.08
Shares withheld for tax withholding obligation (in shares) \| shares			771,141
Tax payment			$ 7,650,000
Phantom RSU
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting installments \| installment	3		3
Stock Appreciation Rights (SARs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting installments \| installment	3		3
Expiration period			10 years
Minimum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period			2 years
Maximum \| Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Award requisite service period			5 years

Share-Based Compensation - Rest

Share-Based Compensation - Restricted Stock Units Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 $ / shares shares
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, weighted average fair value (usd per share) \| $ / shares	$ 0
Granted, weighted average fair value (usd per share) \| $ / shares	2.49
Exercised, weighted average fair value (usd per share) \| $ / shares	3.45
Cancelled/forfeited, weighted average fair value (usd per share) \| $ / shares	3.43
Ending balance, weighted average fair value (usd per share) \| $ / shares	$ 2.49
Time Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	0
Granted (in shares)	3,143
Exercised (in shares)	(2)
Cancelled/forfeited (in shares)	(28)
Ending balance (in shares)	3,113
Market Based RSU
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	0
Granted (in shares)	3,930
Exercised (in shares)	0
Cancelled/forfeited (in shares)	0
Ending balance (in shares)	3,930

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Option Award Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance (in shares) \| shares	14,661
Granted (in shares) \| shares	3,556
Exercised (in shares) \| shares	(1,075)
Cancelled/forfeited (in shares) \| shares	(120)
Ending balance (in shares) \| shares	17,022	14,661
Vested and expected to vest (in shares) \| shares	17,022	14,661
Exercisable (in shares) \| shares	11,208	11,203
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning balance (usd per share) \| $ / shares	$ 1.48
Granted (usd per share) \| $ / shares	3.77
Exercised (usd per share) \| $ / shares	1.53
Cancelled/forfeited (usd per share) \| $ / shares	1.76
Ending balance (usd per share) \| $ / shares	1.95	$ 1.48
Vested and expecting to vest (usd per share) \| $ / shares	1.95	1.48
Exercisable (usd per share) \| $ / shares	$ 1.48	$ 1.44
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, Weighted average remaining contractual term	6 years 2 months 15 days	5 years 9 months 18 days
Vested and expecting, Weighted average remaining contractual term	6 years 2 months 15 days	5 years 9 months 18 days
Exercisable, Weighted average remaining contractual term	4 years 11 months 23 days	5 years 1 month 24 days
Granted, Weighted average remaining contractual term	0 years
Exercised, Weighted average remaining contractual term	0 years
Canceled and forfeited, Weighted average remaining contractual term	0 years
Outstanding, Aggregate intrinsic value \| $	$ 47,653
Vested and expecting to vest, Aggregate intrinsic value \| $	47,653
Exercisable, Aggregate intrinsic value \| $	36,026
Granted, Aggregate intrinsic value \| $
Exercised, Aggregate intrinsic value \| $
Cancelled/forfeited, Aggregate intrinsic value \| $

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Revenues	$ 19,605	$ 8,072	$ 42,168	$ 25,781
Licensing
Related Party Transaction [Line Items]
Revenues	1,515	540	2,902	1,620
Engineering and other services
Related Party Transaction [Line Items]
Revenues	10,912	2,955	25,572	12,630
Equity Method Investee \| Transactions with Equity Method Investees
Related Party Transaction [Line Items]
Accounts receivable	763		763		$ 1,821
Notes receivable	5,351		5,351		0
Accounts payable	635		635		$ 3,195
Related Party \| Licensing
Related Party Transaction [Line Items]
Revenues	1,515	540	2,902	1,620
Related Party \| Engineering and other services
Related Party Transaction [Line Items]
Revenues	$ 104	$ 164	$ 766	$ 496

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
Related Party Transactions - Narrative (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 08, 2023	Nov. 09, 2022
Related Party Transaction [Line Items]
Revenues	$ 19,605,000	$ 8,072,000	$ 42,168,000	$ 25,781,000
Notes receivable, commitment to purchase						$ 5,500,000
Sale of private placement warrants (in shares)					985,278	316,250
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 9.91	$ 0.01
Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Approval of note holders to amend agreement						66.66%
One Tranche Of Notes
Related Party Transaction [Line Items]
Sale of private placement warrants (in shares)						575,000
Amount of Notes purchased						$ 10,000,000
LanzaJet Freedom Pines Fuels LLC
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount						147,000,000
LanzaJet Freedom Pines Fuels LLC \| Senior Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount						$ 113,500,000
Line of credit facility, interest rate						6%
LanzaJet Freedom Pines Fuels LLC \| Subordinated Secured Notes Receivable
Related Party Transaction [Line Items]
Notes receivable, aggregate principal amount						$ 33,500,000
Line of credit facility, interest rate						6%
Related Party Transition Services Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	97,000	23,000	209,000	148,000
Related Party Investment Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	6,000	39,000	446,000	170,000
Related Party Supply Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	0	87,000	75,000	151,000
Cost incurred	199,000	630,000	612,000	893,000
Related Party Licensing Agreement \| Equity Method Investee
Related Party Transaction [Line Items]
Revenues	$ 951,000	$ 0	$ 1,200,000	$ 0

Redeemable, Convertible Prefe_3

Redeemable, Convertible Preferred Stock - Authorized, Issued and Outstanding Shares, Issue Price, and Carrying Value (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Temporary Equity [Line Items]
Shares authorized (in shares)	20,000,000			130,133,670
Shares issued (in shares)	0			129,148,393
Shares outstanding (in shares)	0	0	0	129,148,393	129,148,393	129,148,393	129,148,393	129,148,393
Carrying Amount	$ 0	$ 0	$ 0	$ 480,631	$ 480,631	$ 480,631	$ 480,631	$ 480,631
Series A
Temporary Equity [Line Items]
Shares authorized (in shares)				20,414,445
Shares issued (in shares)				20,414,445
Shares outstanding (in shares)				20,414,445
Carrying Amount				$ 12,230
Series A \| Minimum
Temporary Equity [Line Items]
Issue price (in dollars per share)				$ 0.40
Series A \| Maximum
Temporary Equity [Line Items]
Issue price (in dollars per share)				$ 0.90
Series B
Temporary Equity [Line Items]
Shares authorized (in shares)				7,582,934
Shares issued (in shares)				7,582,934
Shares outstanding (in shares)				7,582,934
Issue price (in dollars per share)				$ 2.37
Carrying Amount				$ 18,000
Series C
Temporary Equity [Line Items]
Shares authorized (in shares)				18,613,084
Shares issued (in shares)				18,121,698
Shares outstanding (in shares)				18,121,698
Issue price (in dollars per share)				$ 3.36
Carrying Amount				$ 60,850
Series D
Temporary Equity [Line Items]
Shares authorized (in shares)				44,946,572
Shares issued (in shares)				44,452,681
Shares outstanding (in shares)				44,452,681
Issue price (in dollars per share)				$ 4.56
Carrying Amount				$ 188,402
Series E
Temporary Equity [Line Items]
Shares authorized (in shares)				22,678,139
Shares issued (in shares)				22,678,139
Shares outstanding (in shares)				22,678,139
Issue price (in dollars per share)				$ 5.23
Carrying Amount				$ 118,076
Series F
Temporary Equity [Line Items]
Shares authorized (in shares)				15,898,496
Shares issued (in shares)				15,898,496
Shares outstanding (in shares)				15,898,496
Issue price (in dollars per share)				$ 5.23
Carrying Amount				$ 83,073

Redeemable, Convertible Prefe_4

Redeemable, Convertible Preferred Stock - Narrative (Details) $ in Thousands		3 Months Ended
	Feb. 08, 2023 USD ($) shares	Mar. 31, 2023 USD ($) shares
Temporary Equity [Line Items]
Conversion ratio	1
In-kind payment of preferred dividend \| $	$ 241,529	$ 241,529
Common stock dividends (in shares)	24,152,942
Common Stock
Temporary Equity [Line Items]
Conversion of preferred stock into common stock (in shares)	153,895,644	153,895,644

Commitment and Contingencies (D

Commitment and Contingencies (Details) - Headquarters In Skokie, Illinois $ in Thousands	Sep. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Lease payments, 2024	$ 3,287
Lease payments, 2025	3,287
Lease payments, 2026	$ 3,287